

CURRICULUM VITAE

Irene Oi-Lin NG

P. 2 - 3	General Information
P. 4 - 29	Research Outputs / Publications
P. 30	Editorship or Editorial Committee Membership of Scholarly Journals
P. 31 - 36	Invited Lectures and Presentations
P. 37 - 38	International Standing and Contributions to Knowledge in the Field
P. 39 - 42	Research Grants, R&D Collaborations and Patents
P. 43 - 47	Teaching and Examinership
P. 48	Professional Standing
P. 49 - 50	Administration
P. 51	Clinical Services

CURRICULUM VITAE**Irene Oi-Lin NG, MD, PhD**

- Loke Yew Professor in Pathology , The University of Hong Kong (HKU)
- Chair Professor in Pathology, HKU
- Director, State Key Laboratory of Liver Research (HKU)

PERSONAL PARTICULARS

Place of Birth: Hong Kong
 Address: Room 07-13, Block T, Department of Pathology, Queen Mary Hospital, Pokfulam, Hong Kong
 Telephone: (852) 2255-2664 or (852) 2255-4658
 Fax: (852) 2872-5197
 E-mail: iolng@hku.hk
 Personal webpage: <http://www.hku.hk/patho/staff/list/ing.html>
<http://hub.hku.hk/cris/rp/rp00335>

EDUCATION

1980 Bachelor of Medicine & Bachelor of Surgery, The University of Hong Kong
 1994 Doctor of Medicine, The University of Hong Kong (HKU)
 2005 Doctor of Philosophy, HKU

MEDICAL QUALIFICATION

1980 Bachelor of Medicine & Bachelor of Surgery, HKU (MBBS)
 1986 Member of the Royal College of Pathologists (U.K.) (MRCPPath)
 1993 Founder Fellow of the Hong Kong College of Pathologists (FHKCPath)
 2019 First Fellow in Genetic and Genomic Pathology, Hong Kong College of Pathologists
 1993 Fellow of the Hong Kong Academy of Medicine (FHKAM)
 1994 Doctor of Medicine (HKU) (MD)
 1997 Fellow of the Royal College of Pathologists (U.K.) (FRCPath)
 1998 Registered Specialist in Pathology, Hong Kong Medical Council
 (Hong Kong Medical Council Registration No.: M04473)
 Specialist Registration No.: S11-0044)

EMPLOYMENTS & POSITIONS

At Department of Pathology, The University of Hong Kong:

1981 - 1986 Clinical Pathologist
 1986 - 1992 Lecturer
 1992 - 1996 Senior Clinical Pathologist (Consultant Pathologist)
 1996 - 2003 Associate Professor
 2003 - 2009 Clinical Professor
 2009 - Present Chair Professor
 2008 - Present Loke Yew Professor in Pathology
 2011 - 2019 Head

HONORARY APPOINTMENTS

1984 Honorary Senior Registrar, Fazakerley Hospital, Liverpool, England
 1989 Honorary Research Fellow, The Royal Free Hospital, London, England
 1989 & 1992 Honorary Research Fellow, Institute of Liver Diseases, King's College School of Medicine and Dentistry, London, England
 1997 Visiting scholar, Dept of Oral Pathology, University of California, San Francisco
 1997 Visiting Professor, Shanghai Cancer Institute, China
 1996 - Present Honorary Consultant, Queen Mary Hospital, Hospital Authority, Hong Kong
 2010 Visiting Professor, Shandong University, China
 2016 - Present Honorary Professor, Peking University Medical College Hospital
 2015.6 – 2016.12 Deputy Chief of Service, Department of Pathology, Queen Mary Hospital

2017 – 2019 Chief of Service, Department of Pathology, Queen Mary Hospital

AWARDS, HONORS, AND SCHOLARSHIPS

1998 and 2008 Mrs. Gordon Wu Exchange Professorship, The University of Hong Kong
 2004 and 2012 Croucher Senior Medical Research Fellowship by Croucher Foundation Hong Kong; a prestigious award to distinguished scientists in Hong Kong
 2005 Outstanding Research Award 2004-2005, HKU
 2008 - Loke Yew Professorship in Pathology, HKU
 2009 Outstanding Research Student Supervisor Award 2007-2008, HKU
 2010 - Director, State Key Laboratory for Liver Research (approved by Ministry of Science and Technology of China)
 2012 Faculty Outstanding Research Output Award
 2012 - 2017 Director, Croucher Summer Course in Cancer Biology, from Croucher Foundation
 2014 - Fellow, American Association for the Study of Liver Disease (FAASLD)
 2012 - Expert, the ‘National Science and Technology Plan Expert Database Service System’, of Ministry of Science and Technology, China
 2014 The World Academy of Science TWAS 2014 prize (Medical Science)
 2017 - 2018 Chair, Special Interest Group “Molecular classification and signaling pathways”, International Liver Cancer Association (ILCA)
 2017 - 2018 Member, Regional Advisory Committee on China, American Association for Cancer Research (AACR)
 2018 - 2019 Author, 5th edition of the World Health Organization (WHO) Classification of Tumors: Digestive System "WHO Blue Books"
 2019 Faculty Outstanding Research Output Awards (2 awards)

MEMBERSHIPS OF PROFESSIONAL SOCIETIES

International Professional Societies

The Royal College of Pathologists (Fellow) (by examination)
 American Association for the Study of Liver Disease (Fellow) (FAASLD)
 American Association for Cancer Research, USA
 International Liver Cancer Association
 Laennec Liver Pathology Society

Local Professional Societies

The Hong Kong College of Pathologists (Council Member 2004 – 2008)
 The Hong Kong Academy of Medicine
 Hong Kong Pathology Society (President 1992 – 93) (Council Member 1993 - 1995)
 Hong Kong Association for the Study of Liver Disease
 Hong Kong Gastroenterology Society (Fellow)

International Study Group

Laennec Society on Liver Pathology (an International liver pathology group)
 International Collaboration on Cancer Reporting (ICCR) for the reporting of intrahepatic, and perihilar cholangiocarcinoma and hepatocellular carcinoma (2014-2020) (ICCR is a collaboration of the Royal College of Pathologists of Australasia (RCPA), the European Society of Pathology (ESP), the Royal College of Pathologists UK, the College of American Pathologists (CAP), and the Canadian Association of Pathologists (CAP-ACP) in association with the Canadian Partnership Against Cancer (CPAC) to develop common, internationally standardised and evidence-based cancer datasets for surgical pathology specimens)

1. RESEARCH OUTPUT / PUBLICATIONS

My research aims to unravel the molecular and cellular mechanisms of liver cancer. The current research of my lab focuses on the integrated functional genomics of liver cancer using genome-scale technologies coupled with clinical translational studies. I have an active program in the basic/translational research of liver cancer, using state-of-the art molecular approaches including genomics, transcriptomics, and single cell analysis, to capture cancer heterogeneity, identify novel subclones, and unravel signaling pathways. I am coupling genomics, genetics, functional molecular analysis and in vivo pre-clinical animal models as well as patient-derived tumor xenograft models to address the molecular mechanisms of this cancer. We work towards translational application for early detection, diagnosis, prognosis and patient stratification towards precision oncology.

Publications

- A total of 421 publications: 2 doctorate theses, 9 book chapters, and 410 articles in journals.
- Top 1% of most cited scientists in ‘Clinical Medicine’ of ISI Essential Science Indicators. Total number of citations: 23,965 (Scopus)/ 19,649 (ISI Web of Science); Citations per paper: 59.61 (Scopus)/ 47.69 (ISI Web of Science) (2020 January), H-index = 85 (Scopus)/ 80 (ISI WoS) (2020 January).

Doctorate theses

- | | |
|----------------------------|---|
| Doctor of Medicine (MD) | Pathobiological prognostic indicators in hepatocellular carcinoma (1994) |
| Doctor of Philosophy (PhD) | Allelic and molecular changes in multistep process of hepatocarcinogenesis (2005) |

Book Chapters

1. **Ng IO**. Primary liver tumours. In Topics in Pathology of Hong Kong, Ho F, Wu PC (Eds), University Press, 1995; pp. 101-114.
2. Fan ST, Lo CM, Cheung ST, Lai CL, **Ng IO**. Lamivudine in liver transplantation. In: Hepatitis B in the Asian-Pacific region, Zuckerman A (Ed), Royal College of Physicians of London, 1999; pp 75-80.
3. **Ng IO**, Qin LF, Liang ZD, Lee TK, Chan CK, Fan ST, Cao L, Ng M. Molecular pathology of hepatocellular carcinoma in Hong Kong. In: Molecular Genetic Basis of Cancer, Lung ML and Hsiao W (Ed), Hong Kong University of Science and Technology, 2001; pp 83-93.
4. Yam JW, Wong CM, **Ng IO**. Deleted in liver cancer 1 (DLC1). In: Encyclopedia of Cancer, M Schwab, 2009; pp 878-880, 2nd Edition, Springer.
5. TK Lee, Castilho A, Ma S, **Ng IO**. Epithelial-mesenchymal transition in cancer stem cell. In: Cancer Stem Cells, Guan XY, 2010; pp 131-143, Transworld Research Network.
6. Wong CM, Yam JW, **Ng IO**. Molecular pathogenesis of hepatocellular carcinoma. In: Molecular Genetics of Liver Neoplasia, Wang XW, Grisham JW & Thorgeirsson SS, 2010; pp 373-396.
7. Alan I, Dawson L, Imai R, Krishnam S, **Ng IO**, Salminen E, Seong J, Stevens G. Trends and practices in diagnosis and treatment of hepatocellular carcinoma. In IAEA Human Health Series. No. 10, International Atomic Energy Agency, United Nations; 2010.
8. Wong CM & **Ng IO**. Genomics of hepatocellular carcinoma. In: Primary Liver Cancer – Challenges and perspectives, Gu JR. 2012; pp 45-63, Springer.
9. Au SL, **Ng IO**, Wong CM. Regulation of EZH2 and its targeted microRNAs. In: Epigenetics and Cancer, Sarkar FH. 2013; pp 33-62, Springer.

Full publications

Journal articles

(Irene O.L. Lui is the maiden name of Irene O.L. Ng)

1. Kung IT, **Lui IO**, Loke SL, Aung Khin M, Mok CK, Lam WK, So SY. Pulmonary scar cancer - a pathologic reappraisal. Am J Surg Pathol 1985; 9: 391-400.
2. **Lui IO**, Kung IT, Lee JM, Boey JH. Primary colorectal signet-ring cell carcinoma in young patients: report of 3 cases. Pathology 1985; 17: 31-35.
3. **Lui IO**, Taylor W, Chin SH. Giant cell arteritis of the uterus and adnexa - case report. Brit J Obst Gynaecol 1985; 92:1064-1066.
4. Ho J, **Lui I**, Hui WM, Ng MM, Lam SK. A study on the correlation of duodenal ulcer healing with campylobacter-like organisms. J Gastroenterol Hepatol 1986; 1: 69-74.
5. Hui WM, Lam SK, Ho J, Ng M, **Lui I**, Lai CL, Lok A, Lau WY, Poon KP, Choi S, Choi TK. Chronic antral gastritis in duodenal ulcer - natural history and treatment with prostaglandin E. Gastroenterology 1986; 91: 1095-1101.
6. Hui WM, Lam SK, Chau PY, Ho J, **Lui I**, Lai CL, Lok ASF, Ng MMT. Persistence of Campylobacter pyloridis despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis. Dig Dis Sci 1987; 32: 1255-1260.
7. Hui WM, Lam SK, Chau PY, Ho J, Lau WY, Poon KP, Lai CL, Lok ASF, **Lui IO**, Ng M. Pathogenetic role of Campylobacter pyloridis in gastric ulcer. J Gastroenterol Hepatol 1987; 2: 309-316.
8. **Ng IO**, Ho J, Ng M. Intestinal metaplasia and gastric carcinoma: a histological study of 198 gastrectomy specimens. J Gastroenterol Hepatol 1988; 3:2 39-245.
9. Lok AS, **Ng IO**. Prochlorperazine induced chronic cholestasis. J Hepatol 1988; 6: 369-373.
10. Ho J, Hui WM, **Ng I**, Lam SK. Natural history of campylobacter pylori in duodenal ulcer treated with an H2-antagonist. Aliment Pharmacol Therap 1989; 3315-332.
11. Hui WM, Lam SK, Ho J, **Ng I**, Lau WY, Branicki FJ, Lai CL, Lok ASF, Ng MMT. Effect of sucralfate and cimetidine on duodenal ulcer-associated antral gastritis and campylobacter pylori. Am J Med 1989; 86: 60-65.
12. **Ng IO**, Fan ST, Nicholls J. Lymphangioma of pancreas. J Gastroenterol Hepatol 1989; 4: 299-302.
13. **Ng IO**, Ng M, Lai EC, Wu PC. Endoplasmic storage disease of liver: intracytoplasmic hyaline inclusions and ground glass hepatocytes. An immune light and electron microscopic characterization. Histopathology 1989; 15: 473-481.
14. Fan ST, **Ng IO**, Lai ECS, Choi TK. Tuberculosis of common bile duct. Am J Gastroenterol 1989; 84: 413-414.
15. Tam AY, **Ng IO**, Cheung PT, Tang TS, Li CH. Haemorrhagic shock encephalopathy. Acta Paed Scand 1989; 78: 458-462.
16. Chan KW, **Lui I**, Chung WB. Marking planes of surgical excision on specimens with mixture of India ink and acetone. J Clin Pathol 1989; 42: 893.
17. Kwong YL, **Ng IO**, Leung SY. Osteolytic skeletal lesion in chronic granulocytic leukemia. Pathology 1990;22: 124-125.
18. **Ng IO**, Leung CY, Ho JW. Fine needle aspiration cytology diagnosis of symptomatic bony metastasis from occult hepatocellular carcinoma - a case report. Diag Cytopathol 1990; 6: 127-129.
19. **Ng IO**, Sturgess RP, Williams R, Portmann B. Ground glass hepatocytes with 'Lafora-like' inclusions - histochemical, immunoperoxidase and electron microscopic characterization. Histopathology 1990;17: 109-115.
20. Lai EC, **Ng IO**, Ng MM, Lok AS, Tam PC, Fan ST, Choi TK, Wong J. Long-term results of resection for large hepatocellular carcinoma: a multivariate analysis of clinicopathological features. Hepatology 1990; 11:815-818.

21. Lai EC, Ng IO, You KT, Tan ES, Wong J. Hepatectomy for large hepatocellular carcinoma: the optimal resection margin. World J Surg 1991;15: 141-145.
22. Lai EC, Ng IO, You KT, Fan ST, Mok FP, Tan ES, Wong J. Hepatic resection for small hepatocellular carcinoma: the Queen Mary Hospital experience. World J Surg 1991;15: 654-659.
23. Ng IO. Hepatitis - a pathological update. J Hong Kong Med Assoc 1991; 43: 26-30.
24. Ng IO, Burroughs AK, Rolles K, Belli L, Scheuer PJ. Hepatocellular ballooning after liver transplantation: a light and electron microscopic study with clinicopathological correlation. Histopathology 1991; 18:323-330.
25. Yuen ST, Ng IO, Ho J, Ma L. Mesocolic lymphangioma - a case report with immunohistochemical and electron microscopic studies. Pathology 1992; 24: 221-223.
26. Cheung AN, Khoo Us, Ng IO. Gastric carcinoma in young Hong Kong Chinese. J Gastroenterol Hepatol 1992; 7: 343-346.
27. Ng IO, Lai EC. Hepatocellular carcinoma with an unusual papillary vesicular appearance. J Gastroenterol Hepatol 1992; 7:232-234.
28. Ng IO, Lai ECS, Ng M, Fan ST. Encapsulation in hepatocellular carcinoma - a pathologic study of 189 cases. Cancer 1992; 70:45-49.
29. Ng IO, Luk IS, Yuen ST, Lau WK, Pritchett CJ, Ng M, Poon GP, Ho J. Surgical lateral clearance in resected rectal carcinomas - a multivariate analysis of clinicopathological features. Cancer 1993; 71: 1972-1976.
30. Shek TW, Ng IO, Chan KW. Inflammatory pseudotumour of the liver - a report of 4 cases and review of literature. Am J Surg Pathol 1993; 17:231-238.
31. Chu KM, Lai EC, Ng IO. Hereditary hemorrhagic telangiectasia involving the ampulla of Vater presented with recurrent gastrointestinal bleeding. Am J Gastroenterol 1993; 88: 1116-1119.
32. Cheung AN, Ng IO. Cytomegalovirus infection of the gastrointestinal tract in non-AIDS patients. Am J Gastroenterol 1993; 88:1882-1886.
33. Ng IO, Ng M. Colonic malacoplakia - unusual association with ulcerative colitis. J Gastroenterol Hepatol 1993; 8: 110-115.
34. Ng IO, Ho J, Pritchett CJ, Chan EY, Coleman S, Ho FC. Use of CEA tissue staining in colorectal cancer patients - correlation with plasma CEA, histology and staging. Pathology 1993; 25: 219-222.
35. Tsui WM, Ng IO, Colombari R, Pea M. Hepatic angiomyolipoma. Histopathology 1993; 22: 602-603.
36. Lai EC, You KT, Ng IO, Shek TW. The pathological basis of resection margin for hepatocellular carcinoma. World J Surg 1993; 17: 786-791.
37. Chan TM, Lok AS, Cheng IK, Ng IO. Chronic hepatitis C after renal transplantation: treatment with interferon-alpha. Transplantation 1993; 56: 1095-1098.
38. Khoo US, Nicholls JM, Lee J, Saing H, Ng IO. Cholestatic liver cell adenoma in a child with hirsutism and elevated serum levels of ACTH and cortisol. Histopathology 1994; 25: 586-588.
39. Campbell F, Appleton MA, Fuller CE, Greeff M, Hallgrimsson J, Katoh R, Ng IO, Satir A, Williams GT, Williams ED. Racial variation in the O-acetylation phenotype of human colonic mucosa. J Pathol 1994; 174: 169-174.
40. Ng IO, Chung LP, Tsang S, Lam CL, Lai ECS, Fan ST, Ng M. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene 1994; 9:985-990.
41. Ng IO, Lai EC, Ho JC, Cheung LK, Ng MM, So MK. Flow cytometric analysis of DNA ploidy in hepatocellular carcinoma. Am J Clin Pathol 1994; 102:80-86.
42. Ng IO, Lai EC, Fan ST, Ng M, Chan AS, So MK. Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in hepatocellular carcinoma. Cancer 1994; 73: 2268-2274.

43. **Ng IO**, Srivastava G, Chung LP, Tsang S, Ng M. Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese People. Cancer 1994; 74:30-37.
44. **Ng IO**, Ng M, Lai EC, Fan ST. Better survival in female patients with hepatocellular carcinoma - possible causes from a pathologic approach. Cancer 1995; 75:18-22.
45. **Ng IO**, Na J, Lai EC, Fan ST, Ng M. Expression of Ki-67 antigen in hepatocellular carcinoma using monoclonal antibody MIB1 - a comparison with proliferating cell nuclear antigen. Am J Clin Pathol 1995; 104:313-318.
46. Ng WK, Lam KY, **Ng IO**. Langerhans' cell histiocytosis: possible association with malignant germ cell tumour. J Clin Pathol 1995; 48: 963-965.
47. Fan ST, Lai EC, Lo CM, **Ng IO**, Wong J. Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg 1995;130: 198- 203.
48. Chan AS, Cheung KN, Chiu KY, **Ng IO**. Effect of fixation on the demonstration of p53 oncoprotein in paraffin-embedded sections. J Hong Kong Med Technol Assoc 1995; 6: 31-36.
49. Peh W, Ngan H, Fan ST, **Ng IO**. Variable imaging appearances of angiomyolipomas of the liver. Brit J Radiol 1995; 68: 540-544.
50. **Ng IO**, Lai EC, Chan AS, So MK. p53 gene overexpression in hepatocellular carcinomas in Hong Kong Chinese - a clinicopathological and prognostic correlation. J Gastroenterol Hepatol 1995; 10:250-255.
51. **Ng IO**, Lai EC, Fan ST, Ng MM, So MK. Prognostic significance of pathologic features of hepatocellular carcinoma - a multivariate analysis of 278 patients. Cancer 1995; 76:2443-2448.
52. **Ng IO**. Pathological features and pathological prognostic indicators in hepatocellular carcinoma. Dig Surg 1995; 12: 16-21.
53. Wang YN, To J, **Ng IO**, Fan ST. A modified method of auxiliary partial liver transplantation in the rat. Hepatogastroenterology 1996; 28:2390-2392.
54. **Ng IO**, Lai KC, Ng M. Clinical and histologic features of gastric antral vascular ectasia - successful treatment with endoscopic laser therapy. J Gastroenterol Hepatol 1996; 11: 270-274.
55. Chan KL, Saing H, Fan ST, Wei W, **Ng IO**, Tsoi NS. Cyclosporin A based immunotherapy for paediatric liver transplantation in Hong Kong. Transplant Proc 1996; 28:1302-1303.
56. Ng WK, Collins RJ, Shek WH, **Ng IO**. Cytologic diagnosis of carcinoma showing thymoma-like element 'CASTLE' of thyroid gland: report of a case with histologic correlation. Diag Cytopathol 1996; 15: 224-227.
57. Ng WK, **Ng IO**. Focal fatty change - a rare hepatic manifestation of diabetes mellitus. Hong Kong Med J 1996; 2:99-101.
58. Shek WH, Ho F, **Ng IO**, Chan AC, Srivastava G, Ma L. Follicular dendritic cell tumor of liver - Evidence for an Epstein-Barr virus-related clonal proliferation of follicular dendritic cells. Am J Surg Pathol 1996; 20:313-324.
59. Fan ST, Lo CM, Chan KL, Lo R, Saing H, Wei W, Lai CL, Tsoi NS, **Ng IO**, Chan JKF, Chau MT, Tso WK, Wong J. Liver transplantation - perspective from Hong Kong. Hepatogastroenterology 1996; 43: 893-897.
60. Fan ST, Lo CM, Man K, Chan KL, Saing H, Wei WI, Lo JW, Lai CL, Choi NS, **Ng IO**, Chau MT, Chan KF, Wong J. Liver transplantation: a report of 23 cases. Chin Med J 1996; 76:267-270.
61. Shek WH, Luk ISC, **Ng IO**, Lo CY. Lymphoepithelioma-like carcinoma of the thyroid gland: lack of evidence of association with Epstein-Barr virus. Hum Pathol 1996; 27: 851-853.
62. **Ng IO**, Ng M, Lai ECS, Fan ST. Pathological features and patient survival in hepatocellular carcinoma in relation to age. J Surg Oncol 1996; 61:134-137.
63. Shek WH, **Ng IO**, Chiu EKW, Chan KW. Pathology of bone marrow transplantation in Hong Kong Chinese. Hong Kong Med J 1996; 2: 133-137.

64. **Ng IO.** Pathological prognostic factors in hepatocellular carcinoma. (Invited review) Cancer J 1996; 9:226-228.
65. Chan KL, Saing H, Fan ST, **Ng IO**, Chan CF, Ha SY, Lau YL. Primary paediatric liver tumours - Queen Mary Hospital experience. Hong Kong J Paed (new series) 1996; 1:60-63.
66. Lam KY, Chan AC, **Ng IO**. Adrenal lipoma: a report of two cases and review of the literature. Scand J Urol Nephrol 1997; 31: 89-90.
67. Lo CM, Fan ST, Liu CL, Wei WI, Lo RJ, Lai CL, Chan JKF, **Ng IO**, Fung A, Wong J. Adult-to-adult living donor liver transplantation using extended right lobe grafts. Ann Surg 1997; 226: 261-270.
68. **Ng IO**, Ng M, Fan ST. Better survival in women with resected hepatocellular carcinoma is not related to tumour cell proliferation nor tumour expression of estrogen and progesterone receptors. Am J Gastroenterol 1997; 92:1355-1358.
69. Lo CM, Fan ST, Liu CL, Lo RJW, Lau GK, Wei WI, Li JH, **Ng IO**, Wong J. Extending the limit on the size of adult recipient in living donor liver transplantation using extended right lobe graft. Transplantation 1997; 63:1524-1528.
70. Fan ST, Liu BC, Lo CM, Man K, **Ng IO**, Wong J. Liver transplantation for alcoholic cirrhosis. Chin J Gen Surg 1997; 6:1-4.
71. Saing H, Fan ST, Chan KL, Wei WI, Lo CM, Mya GH, Tsoi NS, Yuen KY, **Ng IO**, Lo JW, Chau MT, Tso WK, Chan J, Wong J. Liver transplantation in children: the experience of Queen Mary Hospital, Hong Kong. J Pediat Surg 1997; 32:80-83.
72. Fan ST, Lo CM, Lo RJ, Fung KY, Wei WI, Chen YB, Lai CL, **Ng IO**, Yuen KY, Chan JKF, Wong J. Management of fulminant hepatic failure at Queen Mary Hospital. Chin Med J 1997; 110:482-484.
73. Man K, Fan ST, **Ng IO**, Lo CM, Liu CL, Wong J. Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study. Ann Surg 1997; 226:704-713.
74. **Ng IO**, Shek WH, Nicholls J, Ma L. Combined hepatocellular and cholangiocarcinoma - a pathologic study. J Gastroenterol Hepatol 1998; 13:34-40.
75. Lo CM, Fan ST, Liu CL, Lo RJ, Lai CL, Lau GK, Chan JK, **Ng IO**, Wong J. Five-year experience with the development of a liver transplant program in Hong Kong. Transplant Proc 1998; 30:3247-3248.
76. Peh W, Shek TW, **Ng IO**, Lo CM, Fan ST, Ngan H. Imaging of follicular dendritic cell tumours of the liver. J Gastroenterol Hepatol 1998; 13:1146-1151.
77. Shek TW, Liu CL, Peh WCG, Fan ST, **Ng IO**. Intraabdominal follicular dendritic cell tumour: a rare tumour in need of recognition. Histopathology 1998; 33:465-470.
78. Lau H, Fan ST, **Ng IO**, Wong J. Long-term prognosis after hepatectomy for hepatocellular carcinoma. Cancer 1998; 83:2302-2311.
79. **Ng IO.** Molecular and cellular pathology of hepatocellular carcinoma. (Invited review) J Gastroenterol Hepatol 1998; 13:S299-303.
80. Qin LF, **Ng IO**, Fan ST, Ng M. p21, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer 1998; 79:424-428.
81. **Ng IO**, Lam AK, Ng M, Kwong D, Sham J. P-glycoprotein expression of the multidrug-resistance gene is induced by radiation in oral squamous cell carcinomas. Cancer 1998; 83:851-857.
82. Chan KL, Fan ST, Saing H, Wei W, Lo CM, Tsoi NS, **Ng IO**, Chau MT, Tsoi WK, Chan J, Yuen KY, Tam PKH, Wong J. Paediatric liver transplantation in Queen Mary Hospital experience. Chin Med J 1998; 111:610-614.
83. Lam KY, **Ng IO**, Chan GS. Palatal pleomorphic adenoma with florid squamous metaplasia – a potential diagnostic pitfall. J Oral Pathol Med 1998; 27: 407-410.

84. **Ng IO.** Prognostic significance of pathological and biological factors in hepatocellular carcinoma. (Invited review) J Gastroenterol Hepatol 1998; 13:666-670.
85. **Ng IO,** Lee J, Srivastava G, Ng M. Role of insulin-like growth factor II in hepatocellular carcinoma - a study of mRNA and pathological features. J Gastroenterol Hepatol 1998; 13:152-157.
86. Lo CM, Fan ST, Liu CL, Chan KL, **Ng IO,** Lai CL, Lau GK, Fung SK, Wong J. Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong. Transplant Proc 1998; 30:3587-3588.
87. Wang YN, **Ng IO,** To J, Fan ST. A modified method of auxiliary partial liver transplantation in the rat. Hepatogastroenterology 1999; 46:428-431.
88. Yang ZF, Wang WL, Lo CM, **Ng IO,** Fan ST. Acute cellular rejection in liver transplantation. Clin J Org Transplant 1999; 20:237-239.
89. Schoelch ML, Regezi JA, Dekker NP, **Ng IO,** McMillan A, Le AT, Silverman SJR, Fu KK. Cell cycle proteins and the development of oral squamous cell carcinoma. Eur J Cancer B - Oral Oncol 1999; 35:333-342.
90. **Ng IO,** Lam KY, Ng M, Regezi JA. Expression of p21/waf1 in oral squamous cell carcinomas - correlation with p53 and mdm2 genes and cellular proliferation index. Eur J Cancer B - Oral Oncol 1999; 35:63-69.
91. Fan ST, **Ng IO,** Poon RT, Lo CM, Liu CL, Wong J. Hepatectomy for hepatocellular carcinoma - the surgeon's role in long-term survival. Arch Surg 1999; 134:1124-1130.
92. Poon RT, Fan ST, Lo CM, Liu CL, Ngan H, **Ng IO,** Wong J. Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management. Am J Gastroenterol 1999; 94:2460-2466.
93. Tsang WM, Tong AC, **Ng IO.** Intraoral mucoepidermoid carcinoma - a clinicopathological study of four cases. Asian J Oral Maxillofacial Surg 1999; 11:143-148.
94. Lo CM, Fan ST, Lai CL, Liu CL, Yuen MF, **Ng IO,** Wong J. Lamivudine prophylaxis in liver transplantation for hepatitis B in Asian. Transplant Proc 1999; 31:535-536.
95. Saing H, Fan ST, Chan KL, Lo CM, Wei WI, Tsoi NS, Yuen KY, **Ng IO,** Chau MT, Tso WK, Chan JK, Wong J. Liver transplantation in infants. J Pediat Surg 1999; 34:1721-1724.
96. Regezi JA, Dekker NP, McMillan A, Ramirez-Amador V, Meneses-Garcia A, Ruiz-Godoy R, Chrysomali E, **Ng IO.** p53, p21, Rb, MDM2 proteins in tongue carcinoma from patients <35 years vs. >75 years. Eur J Cancer B - Oral Oncol 1999; 35:379-383.
97. Man K, Fan ST, **Ng IO,** Lo CM, Liu CL, Wong J. Tolerance of Pringle maneuver in hepatectomy for liver tumors. Arch Surg 1999; 134:533-539.
98. Lam KY, **Ng IO,** Yuen AP, Kwong DL, Wei WI. Cyclin D1 expression in oral squamous cell carcinomas: clinicopathological relevance and correlation with p53 expression. J Oral Pathol Med 2000; 29:167-172.
99. Poon RT, Fan ST, **Ng IO,** Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89:500-507.
100. **Ng IO,** Liang ZD, Cao L, TW Lee. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines defective in DLC-1. Cancer Res 2000; 60: 6581-6584.
101. Au WY, Ma SK, Kwong YL, **Ng IO,** Hawkins BR, Wan TSK, Liu CL, Fan ST, Lo CM. Graft versus host disease after liver transplantation: documentation by FISH and HLA typing. Clin Transplant 2000; 14:173-176.
102. **Ng IO,** Liu CL, Fan ST, Ng M. Expression of P-glycoprotein in hepatocellular carcinoma - a determinant of chemotherapy response. Am J Clin Pathol 2000; 113:355-363.

103. Poon RT, Fan ST, Lo CM, Liu CL, **Ng IO**, Wong J. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000; 18:1094-1101.
104. Lo CM, Fan ST, Liu CL, Lai CL, Lau GK, Yong BH, **Ng IO**, Young K, Chan JK, Wong J. Liver transplantation in Hong Kong - A wider application. Transplant Proc 2000; 32:2141.
105. Chan KL, S T, Fan, Saing H, Wei W, Lo CM, **Ng IO**, Tsoi NS, Chan J, Tso WK, Yuen KY, Tam PK, Wong J. Liver transplantation is not contraindicated in infancy. Transplantation Proc 2000; 32:2142-2143.
106. **Ng IO**, Xiao L, Lam KY, Yuen PW, Ng M. Microsatellite alterations in squamous cell carcinoma of the head and neck - clustering of loss of heterozygosity in a distinct subset. Eur J Cancer - Oral Oncol 2000; 36:484-490.
107. **Ng IO**, Shek WH, Thung SN, Ye M, Lo CM, Fan ST, Lee JM, Chan KW, Cheung AN. Microsatellite analysis in posttransplant lymphoproliferative disorder to determine donor/recipient origin. Mod Pathol 2000; 11:1180-1185.
108. Chan GS, Ng WK, **Ng IO**, Dickens P. Massive pulmonary tumour embolism due to hepatocellular carcinoma: a diagnosis commonly missed. Forensic Sci Int 2000; 108:215-221.
109. Lo CM, Fan ST, Liu CL, **Ng IO**, Lam BK, Yong BH, Lai CL, Lau GK, Wong J. More effective immunosuppression with the use of FK506 after liver transplantation. Transplant Proc 2000; 32:2269-2270.
110. **Ng IO**, Fan ST. p53 overexpression in hepatocellular carcinoma. (Invited commentary) Arch Surg 2000; 135:1476.
111. Chan KL, Fan ST, Saing H, Wei W, Lo CM, **Ng IO**, Tsoi NS, Chan J, Tso WK, Yuen KY, Tam PK, Wong J. Post liver transplantation stenosis of biliary-enteric anastomoses in infancy: diagnosis and treatment. Transplant Proc 2000; 32:2233-2234.
112. Liu CL, Fan ST, **Ng IO**, Lo CM, Poon RT, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors - a prospective randomized study. Am J Gastroenterol 2000; 95:218-222.
113. Poon RT, Fan ST, **Ng IO**, Wong J. The significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg 2000; 231:544-551.
114. Fan ST, Lo CM, Liu CL, Yong BH, Chan JKF, **Ng IO**. Safety of donors in live-donor liver transplantation using right lobe grafts. Arch Surg 2000; 135:336-340.
115. Yuen MF, Chan TM, Chan OO, **Ng IO**, Lai CL. Acute pancreatitis complicating exacerbation of chronic hepatitis B infection carries a poor prognosis. J Viral Hepatol 2001; 8:459-464.
116. Wong CM, Fan ST, **Ng IO**. β -Catenin mutation and expression in hepatocellular carcinoma - clinicopathological and prognostic significance. Cancer 2001; 92:136-145.
117. Poon RT, **Ng IO**, Fan ST, Lai ECS, Lo CM, Liu CL, Wong J. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001; 19:3037-3044.
118. Qin LF, **Ng IO**. Exogenous expression of p21^{WAF1/CIP1} exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer Lett 2001; 172:7-15.
119. Qin LF, **Ng IO**. Expression of p27^{KIP1} and p21^{WAF1/CIP1} in primary hepatocellular carcinoma. Hum Pathol 2001; 32:778-784.
120. Lee TK, Han JS, Fan ST, Liang ZD, Tian PK, Gu JR, **Ng IO**. Gene delivery using a receptor-mediated gene transfer system targeted to hepatocellular carcinoma cells. Int J Cancer 2001; 93:393-400.
121. Poon RT, Fan ST, Lo CM, **Ng IO**, Liu CL, Wong J. Improving long-term survival after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001; 234:63-70.

122. Lo CM, Cheung ST, Lai CL, Liu CL, **Ng IO**, Yuen MF, Fan ST, Wong J. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001; 233:276-281.
123. Man K, Lo CM, **Ng IO**, Wong YC, Qin LF, Fan ST, Wong J. Liver transplantation in rats using small-for-size grafts - A study of hemodynamic and morphological changes. Arch Surg 2001; 136:280-285.
124. Hui CK, Yuen MF, **Ng IO**, Tsang KWT, Fong GCY, Lai CL. Low molecular weight heparin induced liver toxicity. J Clin Pharmacol 2001; 41:1-4.
125. **Ng IO**, Poon RT, Lee JM, Tso WK, Ng M, Fan ST. Microvessel density, VEGF, its receptors Flt-1 and Flk-1/KDR in human hepatocellular carcinoma. Am J Clin Pathol 2001; 116:838-845.
126. Chim CS, **Ng IO**, Trendell-Smith NJ, Liang R. Primary extramedullary plasmacytoma of the conjunctiva. Leuk Lymphoma 2001; 42:831-834.
127. Poon RT, **Ng IO**, Lau C, Yu WC, Fan ST, Wong J. Serum basic fibroblastic growth factor in hepatocellular carcinoma: correlation with clinicopathologic features and prognosis. Am J Surg 2001; 182:298-304.
128. Poon RT, **Ng IO**, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001; 233:227-235.
129. Li KKW, **Ng IO**, Fan ST, Albrecht JH, Yamashita K, Poon RYC. Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma. Liver 2002; 22:259-268.
130. Wong CM, Lee JM, Lau TCM, Fan ST, **Ng IO**. Clinicopathologic significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin Cancer Res 2002; 8:2266-2272.
131. Lee TK, Lau T, **Ng IO**. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol 2002; 49:78-86.
132. Ho DWY, Lam DK, Chen YB, To J, **Ng IO**, Fan ST. Galactosamine-induced fulminant liver failure - observation in a porcine model. Asian J Surg 2002; 25:73-79.
133. Chen X, Cheung ST, Fan ST, So S, Barry C, Higgins J, Lai KM, Ji J, **Ng IO**, van de Rijn M, Botstein D, Brown PO. Gene expression profiles in human liver cancers. Mol Biol Cell 2002; 13:1929-1939.
134. Qin LF, Lee TK, **Ng IO**. Gene expression profiling by cDNA array in human hepatoma cell line in response to cisplatin treatment. Life Sci 2002; 14:1677-1690.
135. Liu CL, Fan ST, Lo CM, Law WL, **Ng IO**, Wong J. Hepatic resection for colorectal liver metastases: prospective study. Hong Kong Med J 2002; 8:329-333.
136. Chan KL, Lee MF, Guan XY, Fan ST, **Ng IO**. High-density allelotyping on chromosome 8p in hepatocellular carcinoma and clinicopathological correlation. Cancer 2002; 94:3185-3191.
137. **Ng IO**, Poon RT, Shek TWH, Fan ST. Histological activity in noncancerous livers in patients with hepatectomy for hepatocellular carcinoma - clinicopathological correlation and survival analysis. Am J Clin Pathol 2002; 117:411-418.
138. Cheung ST, Chen X, Guan XY, Wong SY, Tai LS, **Ng IO**, So S, Fan ST. Identifying metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multi-nodular tumor. Cancer Res 2002; 62:4711-4721.
139. Qin LF, **Ng IO**. Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett 2002; 175:27-38.
140. Liu CL, Fan ST, Lo CM, **Ng IO**, Wong J. Intraoperative iatrogenic rupture of hepatocellular carcinoma. World J Surg 2002; 26:348-352.

141. Man K, Liang TB, Lo CM, Liu CL, **Ng IO**, Yu WC, Fan ST. The study of hepatic stress gene expression and ultrastructural changes under intermittent Pringle manoeuvre. Hepatobil Pancreat Dis Int 2002; 1: 249-257.
142. Saing H, Fan ST, Tam PKH, Lo CM, Wei WI, Chan KL, Tsoi NS, Yuen KY, **Ng IO**, Chau MT, Tso WK, Wong J. Surgical complications and outcome of pediatric liver transplantation in Hong Kong. J Pediatr Surg 2002; 37:1673-1677.
143. Lo CM, Fan ST, Liu CL, Yong BH, Lai CL, Lau GKK, Wei WI, Tam PKH, **Ng IO**, Young K, Chan JKF, Tso WK, Yuen KY, Wong J. Ten-year experience with liver transplantation at Queen Mary Hospital: retrospective study. Hong Kong Med J 2002; 8:240-244.
144. Poon RT, **Ng IO**, Lau C, Yu WC, Yang ZF, Fan ST, Wong J. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002; 20:1775-1785.
145. Ho MKS, Lee JM, Chan CKL, **Ng IO**. Allelic alterations in nontumorous liver tissues and corresponding hepatocellular carcinoma from Chinese patients Hum Pathol 2003; 34:699-705.
146. Hui CK, Yuen MF, Tso WK, **Ng IO**, Chan AOO, Lai CL. Cholangiocarcinoma in liver cirrhosis. J Gastroenterol Hepatol 2003;18:337-341.
147. Yuen MF, Kato T, Mizokami M, Chan AO, Yuan HJ, Wong DK, Sum SM, **Ng IO**, Fan ST, Lai CL. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003; 39:850-855.
148. Pang A, **Ng IO**, Fan ST, Kwong YL. Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genet Cytogenet 2003;146:8-15.
149. Chan AO, Wong BCY, Lan HY, Loke SL, Chan WK, Hui MM, Yuen YH, **Ng IO**, Hou L, Wong WM, Yuen MF, Luk JMC, Lam SK. Deregulation of cadherin-catenin complex in precancerous lesions of gastric adenocarcinoma. J Gastroenterol Hepatol 2003;18:534-539.
150. **Ng IO**, Guan XY, Poon RT, Fan ST, Lee JMY. Determination of the molecular relationship between multiple tumor nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol2003;199:345-352.
151. Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, Jin DY, **Ng IO**. DLC2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 2003; 278:10824-10830.
152. Man K, Lo CM, Liu CL, Zhang ZW, Lee TK, **Ng IO**, Fan ST, Wong J. Effects of the intermittent Pringle manoeuvre on hepatic gene expression and ultrastructure in a randomized clinical study. Br J Surg 2003;90:183-189.
153. Au WY, Lau GKK, Lie AKW, Liang R, Lo CM, Fan ST, Liu CL, Hawkins BR, **Ng IO**, Kwong YL. Emergency orthotopic liver transplantation for fulminant reactivation of hepatitis B (HBV) after unrelated marrow transplantation. Clin Transplant 2003; 17: 121-125.
154. Tse E, Lie A, **Ng IO**, Kwong YL. Fatal skin rashes and myalgia in a leukemic patient. Haematologica 2003;88:EIM02.
155. Man K, Fan ST, Lo CM, Liu CL, Fung PCW, Liang TB, Lee TK, Tsui SH, **Ng IO**, Zhang ZW, Wong J. Graft injury in relation to graft size in right lobe live donor liver transplantation - a study of hepatic sinusoidal injury in correlation with portal hemodynamics and intra-graft gene expression. Ann Surg 2003; 237:256-264.
156. Liu CL, Fan ST, Lo CM, **Ng IO**, Poon RT, Wong J. Hepatic resection for bilobar hepatocellular carcinoma: Is it justified? Arch Surg 2003;138:100-104.
157. Liu CL, Fan ST, Lo CM, **Ng IO**, Lam CM, Poon RT, Wong J. Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg2003;138:86-90.
158. **Ng IO**, Chan KL, Shek WH, Lee JM, Fong DYT, Lo CM, Fan ST. High frequency of chimerism in transplanted livers. Hepatology 2003;38:989-998. (Featured on cover and with editorial comment)

159. Man K, Lo CM, Lee TK, **Ng IO**, Fan ST. Intragraft gene expression profiles by cDNA microarray in small-for-size liver grafts. Liver Transplant 2003; 9:425-432.
160. Ren Y, Tsui HT, Poon RT, **Ng IO**, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M, Fan ST. Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 2003;107:22-29.
161. Poon RT, Fan ST, **Ng IO**, Wong J. Prognosis after hepatic resection for stage IVA hepatocellular carcinoma - need for reclassification. Ann Surg 2003;237:376-383.
162. Wong WM, Hui CK, Yuen MF, Lai CL, **Ng IO**, Trendell-Smith N, Ooi GC, Fan ST. Reversal of protein-losing enteropathy by liver transplantation. J Clin Gastroenterol 2003;36:86-87.
163. Ma SY, Au WY, **Ng IO**, Lie AKW, Leung AYH, Liang RHS, Lau GKK, Kwong YL. Role of liver biopsy in the management of liver dysfunction after hematopoietic stem cell transplantation in a hepatitis B virus prevalent patient population. Transplantation 2003;76:169-176.
164. Lo CM, Fan ST, Liu CL, Yong BH, Wong Y, **Ng IO**, Wong J. Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transplantation 2003;9:827-832.
165. Wong W, Luk M, **Ng IO**, Hu Y, Liu D, Fan ST. Identification of liver-intestine cadherin in hepatocellular carcinoma - a potential disease marker. Biochem Biophys Res Commun 2003; 311:618-24.
166. Lee TK, Man K, Ling MT, Wang XH, Wong YC, Poon RT, **Ng IO**, Fan ST. Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway. Carcinogenesis 2003; 24:1729-36.
167. Wong CM, Ching YP, Lee JM, Jin DY, **Ng IO**. Genetic and epigenetic alterations on DLC-1 gene in hepatocellular carcinoma. Cancer Res 2003; 63: 7646-7651.
168. Chan AO, **Ng IO**, Lam CM, Shek TW, Lai CL. Cholestatic jaundice caused by sequential carbimazole and propylthiouracil treatment. Hong Kong Med J 2003; 9:377-380.
169. Tong AC, **Ng IO**, Yan BS. Variations in clinical presentations of the simple bone cyst. J Oral Maxillofacial Surg 2003, 61:1487-1491.
170. Liu CL, Fan ST, Lo CM, Wong Y, **Ng IO**, Lam CM, Poon RT, Wong J. Abdominal drainage after hepatic resection is contraindicated in patients with chronic liver diseases. Ann Surg 2004; 239: 194-201.
171. Tsang WM, Tong CK, Chow LTC, **Ng IO**. Massive osteolysis of the maxillofacial skeleton - report of 2 cases involving the mandible. J Oral Maxillofacial Surg 2004; 62:225-30.
172. Ooi GC, Khong PL, Chan GC, Chan KN, Chan KL, Lam W, **Ng IO**, Ha SY. Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients. Br J Haematol 2004;124:385-390.
173. Ng KKC, Poon RT, Lo CM, Liu CL, Lam CM, **Ng IO**, Fan ST. Impact of preoperative fine-needle aspiration cytology on clinical outcome of patients with hepatocellular carcinoma in a tertiary referral center. Arch Surg 2004;139:193-200.
174. Lo CM, Cheung ST, **Ng IO**, Liu CL, Lai CL, Fan ST. Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance – successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. Liver Transplant 2004;10:557-563.
175. Lam CM, Chan AOO, Ho P, **Ng IO**, Lo CM, Liu CL, Poon RT, Fan ST. Differences in clinicopathological features in a cohort of 1,863 young and old patients with hepatitis B related hepatocellular carcinoma. Aliment Pharmacol Therap 2004;19:771-777.
176. Pang R, Yuen J, Yuen MF, Lai CL, Lee TWK, Man K, Poon RT, Fan ST, Wong CM, **Ng IO**, Kwong YL, Tse E. PIN1 over-expression and beta-catenin gene mutations are distinct events in human hepatocarcinogenesis. Oncogene 2004; 23:4182-4186.

177. Lee PKM, Samman N, **Ng IO**. Unicystic ameloblastoma - use of carnoy's solution after enucleation. Int J Oral Maxillofacial Surg 2004;33:263-267.
178. Ma SY, Au WY, **Ng IO**, Lie AKW, Leung AY, Liang R, Lau GK, Kwong YL. Hepatitic graft-versus-host disease after hematopoietic stem cell transplantation: clinicopathologic features and prognostic implication. Transplantation 2004; 77: 1252-1259.
179. Liu CL, Fan ST, Lo CM, Chan SC, **Ng IO**, Lai CL, Wong J. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroid and reduction of tacrolimus dosage. Liver Transplant 2004; 10:728-733.
180. Ma SY, Au WY, Lie AK, **Ng IO**, Leung AY, Tse EW, Liang R, Lau GK, Kwong YL. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34:57-61.
181. Yuen MF, Wong DKH, Sablon E, Tse EWC, **Ng IO**, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histologic and clinical aspects. Hepatology 2004; 39:1694-1701.
182. Lo CM, Fan ST, Liu CL, Yong BH, Wong Y, Lau GKK, Lai CL, **Ng IO**, Wong J. Lessons learned from 100 right lobe living donor live transplants. Ann Surg 2004; 240:151-158.
183. Lee TK, Man K, Poon RT, Lo CM, **Ng IO**, Fan ST. Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma. Oncol Rep 2004;12:25-31.
184. Chan CF, Yau TO, Jin DY, Fan ST, **Ng IO**. Evaluation of nuclear factor- κ B, urokinase-type plasminogen activator (uPA) and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 4140-4149.
185. Ho JC, Cheung ST, Leung PK, **Ng IO**, Fan ST. Decreased expression of cytochrome P450 2E1 is associated with poor prognosis of hepatocellular carcinoma. Int J Cancer 2004; 111:494-500.
186. Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, **Ng IO**, Xu RR, Fan ST. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 2004; 25:2397-2405.
187. Poon RT, Ho JWY, Tong CSW, Lau C, **Ng IO**, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91:1354-1360.
188. Lai AT, Lam CM, Ng KK, Yeung C, Ho WL, Poon LT, **Ng IO**. Hepatic actinomycosis presenting as a liver tumor – Case report and review of literature. Asian J Surg 2004; 27:345-347.
189. Yuen MF, **Ng IO**, Fan ST, Yuan HJ, Wong KH, Yuen CH, Sum SM, Lai CL. Significance of HBV DNA levels in liver histology of HBeAg and anti-HBe positive patients with chronic hepatitis B. Am J Gastroenterol 2004; 99:2032-2037.
190. Chan KL, Guan XY, **Ng IO**. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol 2004; 35: 1324-1331. (Featured on cover and with editorial on it)
191. Pawlik TM., Poon RT, Abdalla EK, Ikai I, Curley SA, Nagorney D, Belghiti J, **Ng IO**, Yamaoka Y, Lauwers G, Vauthey JN. Hepatitis serology defines tumor and liver disease characteristics but not prognosis after resection of hepatocellular carcinoma. J Gastrointest Surg 2004; 8:794-805.
192. Liu CL, Fan ST, Lo CM, Chan SC, Tso WK, **Ng IO**, Wong J. Hepatic resection for incidentaloma. J Gastrointest Surg 2004; 8:785-793.
193. Sze KM, Ching YP, Jin DY, **Ng IO**. Association of MAD2 expression with mitotic checkpoint competence in hepatoma cells. J Biochem Sci 2004; 11:920-927.

194. Cheung ST, Wong SY, Leung KL, Chen X, So S, **Ng IO**, Fan ST. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res 2004; 10:7629-7636.
195. Yau TO, Chan CY, Chan KL, Lee MF, Wong CM, Fan ST, **Ng IO**. HDPR1, a novel inhibitor of the WNT/ β -catenin signaling, is frequently downregulated in hepatocellular carcinoma: Involvement of methylation-mediated gene silencing. Oncogene 2005; 24:1607-1614.
196. Lee TK, Man K, Ho JWY, Wang XH, Poon RT, Sun CKW, Ng KTP, **Ng IO**, Xu R, Fan ST. The significance of Rac signaling pathway in hepatocellular carcinoma cell motility: implication for new therapeutic target. Carcinogenesis 2005; 26: 681-687.
197. Cheung ST, Leung KL, Ip YC, Chen X, Fong DY, **Ng IO**, Fan ST, So S. Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin Cancer Res 2005; 11:551-556.
198. Ho CC, Siu WY, Chow JPH, Lau A, Arooz T, Tong HY, **Ng IO**, Poon RYC. The relative contribution of CHK1 and CHK2 to the Adriamycin-induced checkpoint. Exp Cell Res 2005; 304:1-15.
199. Chin KT, Zhou HJ, Wong CM, Lee JM, Chan CP, Qiang BQ, Yuan JG, **Ng IO**, Jin DY. The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma. Nucl Acid Res 2005; 33: 1859-1873.
200. Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, Ikai I, Yamaoka Y, Curley SA, Nagorney DM, **Ng IO**, Fan ST, Poon RT. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005; 12: 364-373.
201. Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, Kianmanesh R, **Ng IO**, Curley SA, Yamaoka Y, Lauwers GY, Vauthey JN. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005; 137: 403-410.
202. Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA, Nagorney DM, Belghiti J, **Ng IO**, Yamaoka Y, Lauwers GY, Vauthey JN; International Cooperative Study Group on hepatocellular carcinoma. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140: 450-457; discussion 457-458.
203. **Ng IO**. Chimerism in transplanted allografts. (Invited Leading Article). Br J Surg 2005; 92: 661-662.
204. Lo CM, Liu CL, Lau GK, Chan SC, **Ng IO**, Fan ST. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transplant 2005; 11: 807-813.
205. Yuan HJ, Yuen MF, Wong DKH, Sum SM, Sablon E, **Ng IO**, Lai CL. Impact of precore and core mutations on hepatic histology in patients with chronic hepatitis B. Aliment Pharmacol Therap 2005; 22:301-307.
206. Yuen MF, Tanaka Y, **Ng IO**, Mizokami M, Yuen JC, Wong DK, Yuan HJ, Sum SM, Hui CK, Chan AO, Lai CL. Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core promoter and precore mutations. J Viral Hepat 2005; 12: 513-518.
207. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, **Ng IO**, Ikai I, Yamaoka Y, Belghiti J, Lauwers GY, Poon RT, Abdalla EK. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transplant 2005; 11: 1086-1092.
208. Wong CM, Yam JW, Ching YP, Leung TH, Yau TO, Jin DY, **Ng IO**. Rho GTPase activating protein DLC1 (deleted in liver cancer) suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res 2005; 65: 8861-8868.

209. Leung TH, Ching YP, Yam JW, Wong CM, Yau TO, Jin DY, **Ng IO**. Deleted in liver cancer 2, DLC2, suppresses cell transformation via inhibition of RhoA activity. Proc Natl Acad Sci USA 2005; 102:15207-15212.
210. Lee TK, Man K, Ho JW, Wang XH, Poon RT, Xu Y, Ng KT, Chu AC, Sun CK, **Ng IO**, Sun HC, Tang ZY, Xu R, Fan ST. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res 2005; 11:8458-8466.
211. Chan DW, **Ng IO**. Knockdown of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells. J Pathol 2006; 208:372-380.
212. Ng DCH, Chan SF, Kok KH, Yam JWY, Ching YP, **Ng IO**, Jin DY. Mitochondrial targeting of growth suppressor protein DLC2 through the START domain. FEBS Letters 2006; 580:191-198.
213. Luk JM, Lam CT, **Ng IO**, Yu MY, Che CM, Fan ST. Proteomic profiling of hepatocellular carcinoma reveals heat shock proteins (Hsp27, Hsp70, GRP78) up-regulation and associated prognostic value. Proteomics 2006; 6:1049-1057.
214. Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CWK, **Ng IO**, Chan GCF. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin 2006; 30:263-274.
215. Liu CL, Fan ST, Cheung ST, Lo CM, **Ng IO**, Wong J. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg 2006; 244: 194-203.
216. Yam JW, Ko FCF, Chan CY, Jin DY, **Ng IO**. Interaction of Deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res 2006; 66: 8367-8372.
217. Chan DW, Chan CY, Yam JW, Ching YP, **Ng IO**. Prickle-1 promotes degradation of Dishevelled by ubiquitination in liver cancer. Gastroenterology 2006; 131:1218-1227.
218. Yam JW, Ko FCF, Chan CY, Yau TO, Tung EK, Leung TH, Jin DY, **Ng IO**. Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. Hepatology 2006; 44: 881-890.
219. Tong AC, **Ng IO**, Au Yeung KM. Osteomyelitis with proliferative periostitis: an unusual case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102:e14-19.
220. Lee TK, Man K, Poon RT, Lo CM, Yuen AW, **Ng IO**, Ng KT, Leonard W, Fan ST. Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res 2006; 66:9948-9956.
221. Zhang P, Chan DW, Zhu YY, Li JJ, **Ng IO***, Wan DF*, Gu JR Identification and characterization of a putative tumor suppressor gene, CPGL-B, in human hepatocellular carcinoma. Clin Cancer Res 2006; 12:6617-25. (*co-corresponding authors)
222. Lo CM, Fan ST, Liu CL, Chan SC, **Ng IO**, Wong J. Living donor versus deceased donor liver transplantation for early unresectable hepatocellular carcinoma. Br J Surg 2007; 94:78-86.
223. **Ng IO**. The role of pathology and pathologists in the detection and management of cancer (Editorial). Hong Kong Med J 2007; 13: 5-7.
224. Ching YP, Leong VY, Lee MF, Xu HT, Jin DY, **Ng IO**. Pak1 is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving JNK activation and paxillin phosphorylation. Cancer Res 2007; 67: 3601 – 3608.
225. Li HY, Fung KL, Jin DY, Chung SS, Ching YP, **Ng IO**, Sze KH, Ko BC, Sun HZ. Solution structures, dynamics and lipid-binding of the sterile α -motif (SAM) domain of the Deleted in liver cancer 2 (DLC2). Proteins-Structure Funct Bioinform 2007; 67: 1154-1166.
226. Wong CM, Ng YL, Lee MF, Wong CL, Cheung OF, Chan CY, Tung EK, Ching YP, **Ng IO**. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007; 45: 1129-1138.

227. Chan AC, Lo CM, **Ng IO**, Fan ST. Liver transplantation for combined hepatocellular cholangiocarcinoma. Asian J Surg 2007; 30: 143-146.
228. Ho JC, Cheung ST, Poon AW, Lee YT, **Ng IO**, Fan ST. Downregulation of retinol binding protein 5 (RBP5) is associated with aggressive tumor features in hepatocellular carcinoma. J Cancer Res Clin Oncol 2007; 133:929-936.
229. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, **Ng IO**, Fan ST, Wong J. A randomized controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245: 831-842.
230. Ma S, Chan KW, Hu L, Lee TK, Wo JY, **Ng IO**, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem cells. Gastroenterology 2007; 132: 2542-2556.
231. Chen YX, Man K, Ling GS, Chen Y, Cheng Q, Sun BS, Wong OH, Lo CK, **Ng IO**, Lau GK, Huang FP. Superior anti-tumor immunity against hepatocellular carcinoma evoked by dendritic cells devoid of interleukin-10. J Immunol 2007; 179: 6009-6015.
232. Sun CK, Ng KT, Sun BS, Ho JWY, Lee TK, **Ng IO**, Poon RT, Lo CM, Liu CL, Man K, Fan ST. The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence. Br J Cancer 2007; 97:50-57.
233. Leung TH, Yam JW, **Ng IO**. STARD13 (StAR-related lipid transfer (START) domain containing 13). Atlas Genet Cytogenet Oncol Haematol 2007; November.
234. Wong CM, **Ng IO**. Molecular pathogenesis of HCC. (Invited review) Liver Int 2008; 28: 160–174.
235. Wong CC, **Ng IO**. Gene expression profiles of different stages of hepatocarcinogenesis. (**Invited editorial**) J Gastroenterol Hepatol 2008; 23:1-3.
236. Cheung ST, Fan ST, Lee YT, Chow JPH, **Ng IO**, Fong DYT, Lo CM. Albumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinoma. Transplantation 2008; 85: 81-87.
237. Low SC, Peh WC, Muttarak M, Cheung HS, **Ng IO**. Imaging features of hepatic angiomyolipomas. J Med Imaging Radiat Oncol 2008; 52:118-23.
238. Chan DW, Lee JM, Chan PC, **Ng IO**. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma. Int J Cancer 2008, 123:1043-1052.
239. Man K, Lo CM, Xiao JW, Ng KT, Sun BS, **Ng IO**, Cheng Q, Sun CK, Fan ST. The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg 2008; 247: 1049-1057.
240. Lee JM, Wong CM, **Ng IO**. Hepatitis B virus-associated multistep hepatocarcinogenesis - a stepwise increase in allelic alterations. Cancer Res 2008; 68: 5988-5996.
241. Wong CC, Wong CM, Ko FC, Chan LK, Ching YP, Yam JW, **Ng IO**. Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS ONE 2008; 3(July): e2779.
242. Sze KM, Ching YP, Jin DY, **Ng IO**. Role of a novel splice variant of MAD1, MAD1 β , in mitotic checkpoint control in liver cancer. Cancer Res 2008; 68: 9194-9201.
243. Tung EK, Wong CM, Yau TO, Lee JM, Ching YP, **Ng IO**. HAI-2 is epigenetically down-regulated in human hepatocellular carcinoma and its Kunitz domain type 1 is critical for anti-invasive functions. Int J Cancer 2009; 124:1811-1819.
244. Yau TO, Chan CF, Lam S, Cheung OF, Ching YP, Jin DY, Sham MH, **Ng IO**. Hepatocyte-specific activation of NF- κ B does not aggravate chemical hepatocarcinogenesis in transgenic mice. J Pathol 2009; 217: 353-361.
245. Wong CC, Wong CM, Tung EK, Man K, **Ng IO**. Rho-kinase 2 (ROCK2) is frequently overexpressed in hepatocellular carcinoma and involved in tumor progression. Hepatology 2009; 49:1583-1594.

246. Hwang YY, Leung AY, **Ng IO**, Chan GS, Chan KW, Tse E, Kwong YL. Protein losing enteropathy due to T-cell large granular lymphocyte leukemia. J Clin Oncol 2009;27:2097-8.
247. Chang YK, Yang W, Zhao M, Mok CC, Chan TM, Wong RW, Lee KW, Mok MY, Wong SN, **Ng IO**, Lee TL, Ho MH, Lee PP, Wong WH, Lau CS, Sham PC, Lau YL. Association of BANK1 and TNFSF4 with systemic lupus erythematosus in Hong Kong Chinese. Genes Immun 2009; 10:414-20.
248. Yam JW, Tse EY, **Ng IO**. Role and significance of focal adhesion proteins in hepatocellular carcinoma. J Gastroenterol Hepatol 2009; 24:520-530.
249. Maalouf GE, Falissard B, Azoulay D, Callea F, Ferrell LD, Goodman ZD, Hayashi Y, Hsu HC, Hubscher SG, Kojiro M, **Ng IO**, Paterson AC, Reynes M, Zafrani ES, Emile JF. Histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts? J Clin Pathol 2009;62:519-24.
250. Chan LK, Ko FC, **Ng IO***, Yam JW*. Deleted in liver cancer 1 (DLC1) utilizes a previously undocumented binding site for tensin2 PTB domain interaction and required for tumor suppressive function. PLoS ONE 2009;4(5):e5572. (*co-corresponding authors)
251. Lee TK, Castilho A, Ma S, **Ng IO**. Liver cancer stem cells: Implications for a new therapeutic target. Liver Int 2009; 29:955-65.
252. Xu MZ, Yao TJ, Ng IO, Lee NP, Chan YT, Mao M, Dai H, Burchard J, Zender L, Lowe SW, Poon RT, Luk JM. Yes-associated protein is an independent prognostic marker associated with tumor recurrence of hepatocellular carcinoma. Cancer 2009;115:4576-85.
253. Yau TO, Leung TH, Lam S, Cheung OF, Tung EK, Khong PL, Amy Lam Chung SK, **Ng IO**. Deleted in Liver Cancer 2 (DLC2) was dispensable for development and its deficiency did not aggravate hepatocarcinogenesis. PLoS ONE 2009; Aug 10;4(8):e6566.
254. Liu LX, Lee N, Chan V, Xue W, Zender L, Zhang CS, Mao M, Dai HY, Wang XL, Xu M, Lee TK, **Ng IO**, Cheng YC, Kung HF, Lowe S, Poon RT, Wang JH, Luk JM. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 2009; 50: 1453-63.
255. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambros S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, **Ng IO**, Fan J, Tang ZY, Sun HC, Wang XW. Gender and tumor-associated miR-26 is a predictor of hepatitis B-related hepatocellular carcinoma with poor outcome and response to interferon therapy. New Engl J Med 2009;361:1437-47.
256. Hao K, Luk JM, Lee NP, Mao M, Zhang C, Ferguson MD, Lamb J, Dai H, **Ng IO**, Sham PC, Poon RT. Predicting prognostics in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer 2009 Nov 3;9:389 (1-11).
257. Wong H, Yau T, Chan P, **Ng IO**, Chan G, Hui P, Law WL, Lo CM, Hedley AJ, Epstein RJ. PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success. Pathol Oncol Res 2010;16:87-91.
258. Hui IC, Tung EK, Sze KM, Ching YP, **Ng IO**. Rapamycin and CCI-779 inhibit mammalian target of rapamycin (mTOR) signaling in hepatocellular carcinoma. Liver Int 2010 ;30:65-75.
259. Ko FC, Leung TH, Yeung YS, Wong CM, Chan LK, Poon RT, **Ng IO***, Yam JW*. Expression and clinical relevance of deleted in liver cancer (DLC) tumor suppressors in hepatocellular carcinoma. Liver Int 2010; 30:139-48. (*co-corresponding authors)
260. Yam JW, Wong CM, **Ng IO**. Molecular and functional genetics of hepatocellular carcinoma. Front Biosci (Schol Ed) 2010 Jan 1;2:117-34.
261. Sun S, Yi X, Poon RT, Yeung C, Chan KL, **Ng IO**, Day PJR, Luk JM. Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (≤ 2 cm). J Proteome Res 2010; 9:1923-30.
262. Yang W, Shen N, Ye DQ, Liu Q, Zhang Y, Qian XX, Hirankarn N, Ying D, Pan HF, Mok CC, Chan TM, Wong RW, Lee KW, Mok MY, Wong SN, Leung AM, Li XP, Avihingsanon Y, Wong CM, Lee TL, Ho MH, Lee PP, Chang YK, Li PH, Li RJ, Zhang L, Wong WH, **Ng IO**, Lau CS,

- Sham PC, Lau YL; Asian Lupus Genetics Consortium (ALGC). Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet 2010 Feb 12;6(2):e1000841.
263. Chan CP, Mak TY, Chin KT, **Ng IO**, Jin DY. N-Linked glycosylation is required for optimal proteolytic activation of liver-enriched transcription factor CREB-H. J Cell Sci 2010; 123:1438-48.
264. Wong CC, Wong CM, Au SL, **Ng IO**. RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N' Rho move it. Liver Int 2010; 30:642-656.
265. Ko FC, Chan LK, Tung EK, Lowe SW, **Ng IO***, Yam JW*. Akt phosphorylation of Deleted in Liver Cancer 1 abrogates its suppression in liver cancer tumorigenesis and metastasis. Gastroenterology 2010; 139:1397-1407. (*co-corresponding authors) (With editorial Gastroenterology 2010; 139:1093-1096).
266. Lee NP, Poon RT, Shek FH, **Ng IO**, Luk J. Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. Biochem Biophys Acta 2010; 1806:138-45.
267. Leung TH, Yam JW, Chan LK, Ching YP, **Ng IO**. DLC2 (Deleted in liver cancer 2) suppresses cell growth via regulation of Raf-1-ERK1/2-p70S6K signaling pathway. Liver Int 2010; 30:1315-23.
268. Ko FC, **Ng IO**, Yam JW. DLC1 (deleted in liver cancer 1). Atlas Genet Cytogenet Oncol Haematol 2010 May. URL: <http://AtlasGeneticsOncology.org/Genes/DLC1ID40328ch8p22.html>
269. Liang L, Wong CM, Ying Q, Fan DN, Huang S, Ding J, Yao J, Yan M, Li J, Yao M, **Ng IO**, He X. MicroRNA-125b suppressed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology 2010; 52:1731-40.
270. Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K, **Ng IO**. MiR-139 suppresses metastasis and progression of hepatocellular carcinoma through regulation of Rho-kinase 2 (ROCK2). Gastroenterology 2011;140:322-31. **(Top 2% of published articles in biology and medicine, Faculty of 1000 [F1000]).**
271. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, **Ng IO**. Lupeol targets liver tumor initiating cells through PTEN modulation. Hepatology 2011;53:160-70.
272. Yang J, Yang W, Hirankarn N, Ye DQ, Zhang Y, Pan HF, Mok CC, Chan TM, Wong RW, Mok MY, Lee KW, Wong SN, Leung AM, Li XP, Avihingsanon Y, Rianthavorn P, Deekajorndej T, Suphapeetiporn K, Shotlersuk V, Baum L, Kwan P, Lee TL, Ho MH, Lee PP, Wong WH, Zeng S, Zhang J, Wong CM, **Ng IO**, Garcia-Barceló MM, Cherny SS, Tam PK, Sham PC, Lau CS, Lau YL. ELF1 is associated with systemic lupus erythematosus in Asian populations. Hum Mol Genet 2010; 20:601-7.
273. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, **Ng IO**, Man K, Wong N, To KF, Zheng BJ, Lai PB, Chan KW, Guan XY. miR-130b promotes CD133+ liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010;7: 694-707.
274. Chan SC, Lo CM, Ng KK, **Ng IO**, Yong BH, Fan ST. Portal inflow and pressure changes in right liver living donor liver transplantation including the middle hepatic vein. Liver Transpl 2011; 17:115-21.
275. Wong CM, Wong CC, Ng YL, Ko FC, **Ng IO**. Transcriptional repressive H3K9 and H3K27 methylations are essential for DNMT1-mediated DNA methylation recovery. PLoS ONE 2011;6(2): e16702.
276. Zhang Y, Yang W, Mok CC, Chan TM, Wong RW, Mok MY, Lee KW, Wong SN, Leung AM, Lee TL, Ho MH, Lee PP, Wong WH, Yang J, Zhang J, Wong CM, **Ng IO**, Garcia-Barceló MM, Cherny SS, Tam PK, Sham PC, Lau CS, Lau YL. Two missense variants in UHRF1BP1 are independently associated with systemic lupus erythematosus in Hong Kong Chinese. Genes Immun 2011;12:231-4.
277. Chan J, Ko FC, Yeung YS, **Ng IO**, Yam JW. Integrin-linked Kinase overexpression and its

- oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. PLoS ONE 2011; Feb 9;6(2):e16984.
278. Mak GW, Chan MM, Leong VY, Lee JM, Yau TO, **Ng IO**, Ching YP. Overexpression of a novel activator of PAK4, CDK5RAP3, promotes hepatocellular carcinoma metastasis. Cancer Res 2011; 71:2949-2958.
 279. Arzumanyan A, Friedman T, **Ng IO**, Clayton MM, Lian Z, Feitelson MA. Does hepatitis B x antigen (HBx) promote the appearance of liver cancer stem cells? Cancer Res 2011; 71:3701-8.
 280. Seto WK, Ng M, Chan P, **Ng IO**, Cheung SC, Hung IF, Yuen MF, Lai CL. Ketamine-induced cholangiopathy: a case report. Am J Gastroenterol 2011;106:1004-5.
 281. Sze KM, Wong KL, Chu GK, Yau TO, **Ng IO**. Loss of PTEN enhances cell invasion and migration through AKT/Sp-1 transcription factor/MMP2 activation and has clinicopathologic significance in hepatocellular carcinoma. Hepatology 2011;53:1558-69.
 282. Gao P, Wong CC, Tung EK, Lee JM, Wong CM, **Ng IO**. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol 2011; 54:1177-84.
 283. Luk SU, Lee TK, Liu J, Lee DT, Chiu YT, Ma S, **Ng IO**, Wong YC, Chan FL, Ling MT. Hemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. PLoS One 2011;6(5):e19804.
 284. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, **Ng IO**. CD24⁺ liver tumor-initiating cells drive self-renewal and tumor initiation through Stat3-mediated nanog regulation. Cell Stem Cell 2011; 9:50-63 (IF 25.9; Rank 4 of 162 in Cell Biology Category; a '*Featured Research*' paper in *Cell Stem Cell* in 2012 September).
 285. Arzumanyan A, Friedman T, Kotei E, **Ng IO**, Lian Z, Feitelson MA. Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer. Oncogene 2012;31: 563-72.
 286. Chew V, Chen JM, Lee DM, Loh E, Lee JM, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Toh HC, Lucien L, Ooi PJ, Heikenwalder M, **Ng IO**, Nardin A, Abastado JP. An immune gene signature predictive for survival in early hepatocellular carcinoma: role of chemokine-driven lymphocyte infiltration. Gut 2012;61:427-38.
 287. Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, Fraley SI, Wong CM, Khoo US, **Ng IO**, Wirtz D, Semenza GL. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A 2011;108:16369-74.
 288. Tung EK, Mak CK, Fatima S, Zhao H, Lo RC, Zhang CS, Dai H, Poon RT, Yuen MF, Lai CL, Li JJ, Luk JM, **Ng IO**. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liv Int 2011; 31:1494-1504.
 289. Chan LK, Ko FC, Sze KM, **Ng IO***, Yam JW*. Nuclear-Targeted Deleted in Liver Cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo. PLoS ONE 2011;6:e25547. (Co-corresponding authors)
 290. Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, **Ng IO**, Man K, To KF, Lai PB, Lo CM, Guan XY, Chan KW. CD133⁺ liver tumor-initiating cells promote tumor angiogenesis, growth and self-renewal through neurotensin/IL-8/CXCL1 signaling. Hepatology 2012; 55:807-20.
 291. Li R, Yang WL, Zhang J, Hirankarn N, Pan HF, Mok CC, Chan TM, Wong RWS, Mok MY, Lee KW, Wong SN, Leung AMH, Li XP, Avihingsanon Y, Lee TL, Ho MHK, Lee PPW, Sang WH, Wong, Wong CM, **Ng IO**, Yang J, Li PH, Zhang Y, Zhang L, Li WX, Baum L, Kwan P, Rianthavorn P, Deekajorndej T, Suphapeetiporn K, Shotlersuk V, Garcia-Barcelo M, Cherny SS, Tam PK, Sham PC, Lau CS, Shen N, Lau YL, Ye DQ. Association of CD247 with systemic lupus erythematosus in Asian Populations: A genome wide association study. Lupus 2011; 21: 75-83.
 292. Tse EY, Ko FC, Tung EK, Chan LK, Lee TK, Hui LJ, Ngan ES, Wong AS, **Ng IO**, Yam JW. Caveolin-1 promotes hepatocellular carcinoma tumourigenesis, migration and invasion via Met-

- ERK1/2 pathway. *J Pathol* 2012; 226:645-53.
293. Hao K, Lamb J, Zhang C, Xie T, Wang K, Zhang B, Chudin E, Lee NP, Mao M, Zhong H, Greenawalt D, Ferguson MD, **Ng IO**, Sham PC, Poon RT, Molony C, Schadt EE, Dai H, Luk JM. Clinicopathologic and gene expression parameters predicts liver cancer prognosis. *BMC Cancer* 2011;11:481.
 294. Lo RC, **Ng IO**. Hepatocellular tumors – Immunohistochemical analyses for classification and prognostication. *Chin J Cancer Res* 2011; 43:245-253.
 295. Wong CM, Wong CC, Lee JM, Fan DNY, Au SL, **Ng IO**. Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis. *Hepatology* 2012; 55:1453-61. **(Featured on cover) (Faculty of 1000 (F1000) - the top 2% of published articles in biology and medicine).**
 296. Chan KY, Wong CM, Kwan JS, Lee KM, Cheung KW, Yuen MF, Lai CL, Poon RT, Sham PC, **Ng IO**. GWAS identified 8p12 locus that is associated with susceptibility to hepatocellular carcinoma in Southern Chinese patients with chronic HBV infection. *PLoS One* 2011;6(12):e28798.
 297. Chan FK, Chung SS, **Ng IO**, Chung SK. The RhoA GTPase-activating protein DLC2 modulates RhoA activity and hyperalgesia to noxious thermal and inflammatory stimuli. *Neurosignals* 2012;20(2):112-26.
 298. Wong CM, **Ng IO**. Reply to: "Deregulation of microRNAs expression occurs in stages of multiple hepatocarcinogenesis: why it is different?". *J Hepatol* 2012; doi: 10.1016/j.jhep.2011.12.005.
 299. Fatima S, Lee NP, Tsang FH, Kolligs FT, **Ng IO**, Poon RT, Fan ST, Luk JM. Dickkopf 4 (DKK4) acts on Wnt/ β -catenin pathway by influencing β -catenin in hepatocellular carcinoma. *Oncogene* 2012; 31:4233-44 .
 300. Yuan K, Lian Z, Sun B, Clayton MM, **Ng IO**, Feitelson MA. Role of miR-148a in hepatitis B associated hepatocellular carcinoma. *PLoS One*. 2012;7(4):e35331.
 301. Tung EK, Wong BY, Yau TO, **Ng IO**. Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion. *PLoS ONE* 2012; 7(5):e36565.
 302. Au SL, Wong CC, Lee JM, Fan DN, **Ng IO***, Wong CM*. Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs to promote liver cancer metastasis. *Hepatology* 2012; 55:1453-61. (*co-corresponding authors)
 303. Lai WL, Hung WY, Wong LL, Zhou Y, Leong VY, Lee JM, **Ng IO**, Jin DY, Ching YP. The centrosomal protein Tax1 binding protein 2 is a novel tumour suppressor in hepatocellular carcinoma regulated by cyclin-dependent kinase 2. *Hepatology* 2012; 56:1770-81.
 304. Chen L, Liu C, Ko FC, Xu N, **Ng IO**, Yam JW, Zhu G. Solution structure of the PTB domain of human Tensin2 in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode. *J Biol Chem* 2012; 287:26104-14.
 305. Lee CW, Wong LL, Tse EY, Liu HF, Leong VY, Lee JM, Hardie DG, **Ng IO**, Ching YP. AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. *Cancer Res* 2012;72:4394-404.
 306. Lam CY, Yip CW, Poon TC, Cheng CK, Ng EW, Wong NC, Cheung PF, Lai PB, **Ng IO**, Fan ST, Cheung ST. Identification and characterization of tropomyosin 3 associated with granulin-epithelin precursor in human hepatocellular carcinoma. *PLoS One* 2012;7:e40324.
 307. Lee TK, Cheung VC, **Ng IO**. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. *Cancer Lett* 2013; 338:101-9.
 308. Sze KM, Chu GK, Lee JM, **Ng IO**. C-terminal truncated HBx is associated with metastasis and enhances invasiveness via C-Jun/MMP10 activation in hepatocellular carcinoma. *Hepatology* 2013;57:131-139.
 309. Ma W, Wong CC, Tung EK, Wong CM, **Ng IO**. RhoE is frequently downregulated in HCC and

- suppresses HCC invasion through antagonizing the Rho/ROCK/MYPT pathway. Hepatology 2013;57:152-161.
310. Tung EK, **Ng IO**. Reply to “Considerations in the significance of Dickkopf-1 levels in human hepatocellular carcinoma”. Liver Int 2012; Aug 16.
 311. Mak GW, Lai WL, Zhou Y, Li M, **Ng IO**, Ching YP. CDK5RAP3 is a novel repressor of p14ARF in hepatocellular carcinoma cells. PLoS One 2012;7(7):e42210.
 312. Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M, **Ng IO**, Nardin A, Abastado JP. TLR3-expressing tumor parenchyma and infiltrating NK cells promote tumor control in hepatocellular carcinoma patients. J Natl Cancer Inst 2012;104:1796-807.
 313. Tung EK, **Ng IO**. Significance of serum DKK1 as a diagnostic biomarker in hepatocellular carcinoma. Future Oncol 2012;8:1525-8.
 314. Fan DN, Tsang FH, Tam AH, Au SL, Wong CC, Wei L, Lee JM, He X, **Ng IO**, Wong CM. Histone lysine methyltransferase, SUV39H1, promotes HCC progression and is negatively regulated by microRNA-125b. Hepatology 2013;57:637-47.
 315. Wong CM, Kai AK, Tsang FH, **Ng IO**. Regulation of hepatocarcinogenesis by microRNAs. Front Biosci (Elite Ed) 2013;5:49-60.
 316. Yang W, Tang H, Zhang Y, Tang X, Zhang J, Sun L, Yang J, Cui Y, Zhang L, Hirankarn N, Cheng H, Pan HF, Gao J, Lee TL, Sheng Y, Lau CS, Li Y, Chan TM, Yin X, Ying D, Lu Q, Leung AM, Zuo X, Chen X, Tong KL, Zhou F, Diao Q, Tse NK, Xie H, Mok CC, Hao F, Wong SN, Shi B, Lee KW, Hui Y, Ho MH, Liang B, Lee PP, Cui H, Guo Q, Chung BH, Pu X, Liu Q, Zhang X, Zhang C, Chong CY, Fang H, Wong RW, Sun Y, Mok MY, Li XP, Avihingsanon Y, Zhai Z, Rianthavorn P, Deekajorndej T, Suphapeetiporn K, Gao F, Shotelersuk V, Kang X, Ying SK, Zhang L, Wong WH, Zhu D, Fung SK, Zeng F, Lai WM, Wong CM, **Ng IO**, Garcia-Barceló MM, Cherny SS, Shen N, Tam PK, Sham PC, Ye DQ, Yang S, Zhang X, Lau YL. Meta-Analysis Followed by Replication Identifies Loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as Associated with Systemic Lupus Erythematosus in Asians. Am J Hum Genet 2013; 92:41-51.
 317. Lo RC, Chan SC, Chan KL, Chiang AK, Lo CM, **Ng IO**. Post-transplant lymphoproliferative disorders in liver transplant recipients - A clinicopathologic study. J Clin Pathol 2013; 66:392-8.
 318. Ko FC, Chan LK, Sze KM, Yeung YS, Tse EY, Lu P, Yu MH, **Ng IO**, Yam JW. PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis. Nat Commun 2013;4:1618.
 319. Au SL, **Ng IO**, Wong CM. Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins. Front Med 2013;7:231-41.
 320. Au SL, Wong CC, Lee JM, Wong CM, **Ng IO**. EZH2-mediated H3K27me3 is involved in epigenetic repression of Deleted in Liver Cancer 1 in human cancers. PLoS One 2013; 8(6):e68226.
 321. Lo RC, **Ng IO**. Hepatic progenitor cells: Their role and functional significance in the new classification of primary liver cancers. Liver Cancer 2013;2:84-92.
 322. Wong CC, Kai AK, **Ng IO**. The impact of hypoxia in hepatocellular carcinoma metastasis. Front Med 2014;8:33-41.
 323. Fung J, Lai CL, Yuen MF, **Ng IO**. Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B? Hepatobiliary Surg Nutr 2013;2:34-6.
 324. Lo J, Lin **Ng IO**, Lee TK. CD47, a potential therapeutic target for hepatocellular carcinoma. J Liver: Dis Transplant 2013; 2:2. doi:10.4172/2325-9612.1000e105.
 325. Lau EY, **Ng IO**, Lee TK. Cancer associated fibroblasts and hepatocellular carcinoma. J Liver: Dis & Transplantation 2013; Editorial.
 326. Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, **Ng IO**, Sun H, Qin L, Qiu S, Lee JM, Lo CM, Man K,

- Yang Y, Yang Y, Yang Y, Zhang Q, Zhu X, Li N, Wang Z, Ding G, Zhuang SM, Zheng L, Luo X, Xie Y, Liang A, Wang Z, Zhang M, Xia Q, Liang T, Yu Y, Cao X. Hepatic RIG-I predicts survival and interferon- α therapeutic response in hepatocellular carcinoma. Cancer Cell 2014;25:49-63. (Featured on cover)
327. Sze KM, Chu GK, Mak QH, Lee JM, Ng IO. Proline-rich acidic protein 1 (PRAP1) is a novel interacting partner of MAD1 and has suppressive role in mitotic checkpoint signaling in HCC. J Pathol 2014; 233:51-60.
328. Lee TK, Cheung VC, Lu P, Lau EY, Ma S, Tang KH, Tong C, Ng IO. Blockade of CD47 mediated CTSS-PAR2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 2014;60:179-91.
329. Jing Y, Jia DS, Wong CM, Ng IO, Zhang ZF, Liu L, Wang QF, Zhao FY; Li JJ, Yao M, Wu XZ, He XH. SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin beta 1 signaling pathway in hepatocellular carcinoma. Mol Oncol 2014; 8:366-377.
330. Kido T, Lo RC, Li Y, Lee JM, Tabatabai L, Ng IO, Lau YF. The potential contributions of a Y-located proto-oncogene and its X-homologue in sexual dimorphisms in hepatocellular carcinoma. Hum Pathol 2014;45:1847-58.
331. Wong CC, Tse AP, Huang YP, Zhu YT, Chiu DK, Au SL, Kai AK, Lee JM, Wei LL, Tsang FH, Lo RC, Shi J, Zheng YP, Wong CM, Ng IO. Deregulation of Lysyl Oxidase-Like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma metastasis. Hepatology 2014; 60:1645-58.
332. Liu J, Lau EY, Chen J, Yong J, Tang KD, Lo J, Ng IO, Lee TK, Ling MT. Polysaccharopeptide enhanced the anti-cancer effect of gamma-tocotrienol through activation of AMPK. BMC Complement Altern Med 2014;14:303.
333. Wong NC, Cheung PF, Yip CW, Chan KF, Ng IO, Fan ST, Cheung ST. Antibody against granulinsensitizes hepatocellular carcinoma to chemotherapeutic agents. Mol Cancer Ther 2014;12:3001-12.
334. Cheung PF, Yip CW, Wong NC, Fong D, Wan AM, Cheung TT, Ng IO, Poon RT, Fan ST, Cheung ST. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity. Cancer Immunol Res 2014; 12:1209-19.
335. Tang HM, Gao WW, Chan CP, Cheng Y, Chaudhary V, Deng JJ, Yuen KS, Wong CM, Ng IO, Kok KH, Zhou J, Jin DY. Requirement of CRTCL1 coactivator for hepatitis B virus transcription. Nucleic Acids Res 2014;42:12455-68.
336. Zhang Y, Zhang J, Yang J, Wang Y, Zhang L, Zuo X, Sun L, Pan HF, Hirankarn N, Wang T, Chen R, Ying D, Zeng S, Shen JJ, Lee TL, Lau CS, Chan TM, Leung AM, Mok CC, Wong SN, Lee KW, Ho MH, Lee PP, Chung BH, Chong CY, Wong RW, Mok MY, Wong WH, Tong KL, Tse NK, Li XP, Avihingsanon Y, Rianthavorn P, Deekajorndej T, Suphapeetiporn K, Shotelersuk V, Ying SK, Fung SK, Lai WM, Wong CM, Ng IO, Garcia-Barcelo MM, Cherny SS, Tam PK, Sham PC, Yang S, Ye DQ, Cui Y, Zhang XJ, Lau YL, Yang W. Meta-analysis of GWAS on two Chinese populations followed by replication identifies novel genetic variants on the X chromosome associated with systemic lupus erythematosus. Hum Mol Genet 2015;24:274-84.
337. Tsang FH, Au SL, Wei L, Fan DN, Lee JM, Wong CC, Ng IO*, Wong CM*. Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumor suppressive miR-125b. Liver Int 2015;35:1597-606. (*Co-corresponding author)
338. Ho DW, Ng IO. uGPA: unified Gene Pathway Analyser package for high-throughput genome-wide screening data provides mechanistic overview on human diseases. Clin Chim Acta 2015; 441:105-8.
339. Wong CC, Au SL, Tse AP, Xu IM, Lai RK, Wei LL, Fan DN, Tsang FH, Wong CM, Ng IO. Down-regulation of miR-122 induces switch of pyruvate kinase isoforms from PKL to PKM to promote hepatocellular carcinoma development. PLoS ONE 2014;9:e115036.
340. Leung CO, Wong CC, Fan DN, Kai AK, Tung EK, Xu IM, Ng IO*, Lo RC*. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma. Oncotarget 2015;6:

- 10880-92. (Recommended in F1000Prime) *Co-corresponding authors.
341. Zhang Y, Yang J, Zhang J, Sun L, Hirankarn N, Pan HF, Lau CS, Chan TM, Lee TL, Leung AM, Mok CC, Zhang L, Wang Y, Shen JJ, Wong SN, Lee KW, Ho MH, Lee PP, Chung BH, Chong CY, Wong RW, Mok MY, Wong WH, Tong KL, Tse NK, Li XP, Avihingsanon Y, Rianthavorn P, Deekajorndej T, Suphapeetiporn K, Shotelersuk V, Ying SK, Fung SK, Lai WM, Wong CM, **Ng IO**, Garcia-Barcelo MM, Cherny SS, Cui Y, Sham PC, Yang S, Ye DQ, Zhang XJ, Lau YL, Yang W. Genome-wide search followed by replication reveals genetic interaction of CD80 and ALOX5AP associated with systemic lupus erythematosus in Asian populations. *Ann Rheumat Dis* 2015; Apr 10.
 342. Zhang Y, Wang YF, Yang J, Zhang J, Sun L, Hirankarn N, Pan HF, Lau CS, Chan TM, Lee TL, Leung AM, Mok CC, Zhang L, Shen JJ, Wong SN, Lee KW, Ho MH, Lee PP, Chung BH, Chong CY, Wong RW, Mok MY, Wong WH, Tong KL, Tse NK, Li XP, Avihingsanon Y, Rianthavorn P, Deekajorndej T, Suphapeetiporn K, Shotelersuk V, Ying SK, Fung SK, Lai WM, Wong CM, **Ng IO**, Garcia-Barcelo MM, Cherny SS, Tam PK, Sham PC, Yang S, Ye DQ, Cui Y, Zhang XJ, Yang W, Lau YL. Meta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus. *Arthritis Res Ther* 2015 Mar 20;17:67. doi: 10.1186/s13075-015-0577-6.
 343. Wong CM, Wei L, Au SL, Fan DN, Zhou Y, Tsang FH, Lee JM, He XH, Shi J, Wong CC, **Ng IO**. miR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway and suppresses HCC metastasis. *Oncotarget* 2015;6:13658-70.
 344. Chan LK, Chiu YT, Sze KM, **Ng IO**. Tensin4 is upregulated by EGF-induced ERK1/2 activity and promotes cell proliferation and migration in hepatocellular carcinoma. *Oncotarget* 2015; 2015;6:20964-76.
 345. Lo J, Lau EY, Ching RH, **Ng IO***, Lee TK*. NF-KB mediated CD47 upregulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma. *Hepatology* 2015; 62: 534–545. *Co-corresponding authors.
 346. Ho DW, Sze KM, **Ng IO**. Virus-Clip: a fast and memory-efficient viral integration site detection tool at single-base resolution. *Oncotarget* 2015; 6:20959-63.
 347. **Ng IO**, Sze KM, Chu GK. Role of hepatitis B virus X protein in liver cancer. *Hong Kong Med J* 2015;21 Suppl 4:27-30.
 348. Ho DW, Kai AK, **Ng IO**. TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma. *Fronts Med* 2015; 9:322-30.
 349. Tsang FH, Au SL, Wei L, Fan DN, Lee JM, Wong CC, **Ng IO***, Wong CM*. MicroRNA-142-3p and microRNA-142-5p are down-regulated in hepatocellular carcinoma and have synergistic effects on cell motility. *Front Med* 2015; 9:331-43.*Co-corresponding authors.
 350. Fung J, Lo R, Chan SC, Chok K, Wong T, Sharr W, Cheung TT, Chan AC, Dai WC, Sin SL, **Ng IO**, Lai CL, Yuen MF, Lo CM. Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone. *Liver Transpl* 2015; 21:1504-10.
 351. Lo J, Lau EY, So FT, Ping L, Chan VS, Cheung VC, Ching RH, Cheng BY, Ma MK, **Ng IO***, Lee TK*. Anti-CD47 antibody suppresses tumor growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. *Liver Int* 2016; 36:737-45. *Co-corresponding authors.
 352. Ching RH, Lau EY, Ling PM, Lee JM, Ma MK, Cheng BY, **Ng IO***, Lee TK*. Phosphorylation of nucleophosmin at threonine 234/237 is associated with HCC metastasis. *Oncotarget* 2015; 6:43483-95. *Co-corresponding authors.
 353. Wong CM, Lai W, Law CT, Ho DW, Tsang FH, Au SL, Sze KM, Lee JM, Wong CC, **Ng IO**. Upregulation of histone methyltransferase SETDB1 expression by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. *Hepatology* 2016; 63:474-87.
 354. Garnelo M, Tan A, Her ZS, Yeong J, Lim CJ, Chen J, Lim KH, Weber A, Chow P, Chung A, Ooi LL, Toh HC, Heikenwalder M, **Ng IO**, Nardin A, Chen Q, Abastado JP, Chew V. Interaction

- between tumor-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut 2017;66:342-351.
355. Xu IM, Lai RK, Lin SH, Tse AP, Chiu DK, Koh HY, Law CT, Wong CM, Cai ZW, Wong CC, **Ng IO**. Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci USA 2016;113:E725-34.
356. Lai RK, Xu IM, Tse AP, Chiu DK, Wei LL, Wong CM, Wong MP, **Ng IO***, Wong CC*. NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4-like 2 (NDUFA4L2) is critical to hepatocellular carcinoma development through reducing oxidative stress. Clin Cancer Res 2016; 22: 3105-17. *Co-corresponding authors.
357. Chiu YT, Wong JK, Choi SW, Sze KM, Ho DW, Chan LK, Man K, Cherny S, Yang WL, Wong CM, Sham PC, **Ng IO**. Novel pre-mRNA splicing of intronic integrated HBV in generation of oncogenic chimera in hepatocellular carcinoma. J Hepatol 2016; 64: 1256-64.
358. Kai AK, Chan LK, Lo RC, Lee JM, Wong CC, Wong CM, **Ng IO**. Downregulation of TIMP2 via HIF-1/ miR-210/HIF-3 regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. Hepatology 2016; 64:473-87.
359. Leung CO, Mak WN, Kai AK, Chan KS, Lee TK, **Ng IO***, Lo RC*. Sox9 confers stemness properties in hepatocellular carcinoma through Frizzled-7 mediated Wnt/ β -catenin signaling. Oncotarget 2016;7:29371-86. *Co-corresponding authors.
360. Lau EY, Lo J, Lee JM, Ng JK, Chai S, Lin N, Ma S, **Ng IO***, Lee TK*. Cancer-associated fibroblast-derived hepatocyte growth factor (HGF) regulates tumorigenicity and self-renewal in hepatocellular carcinoma through c-Met/FRA1/HEY1 signaling. Cell Rep 2016;15:1175-89. *Co-corresponding authors.
361. Wong CC, Wong CM, **Ng IO**. Editorial: Hormonal control of the metabolic machinery of hepatocellular carcinoma. HepatoBiliary Surg Nutr 2016; 5:195-7.
362. Ma W, Sze KM, Chan LK, Lee JM, Lai LW, Wong CM, Lee TK, Wong CC, **Ng IO**. RhoE/ROCK2 regulates chemoresistance through NF- κ B/IL-6/STAT3 pathway in hepatocellular carcinoma. Oncotarget 2016; 7:41445-41459.
363. Chiu DK, Lai RK, Tse AP, Xu IM, Wei LL, Wong CM, Lo RC, **Ng IO***, Wong CC*. Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. Hepatology 2016;64:797-813. *Co-corresponding authors.
364. Chiu YT, **Ng IO**. Gender disparity of hepatocellular carcinoma: role of hepatitis B virus X protein and androgen receptor. Hong Kong Med J 2016; 22 Suppl 4(3):43-47.
365. Xu HT, Lai WL, Liu HF, Wong LL, **Ng IO**, Ching YP. PAK4 phosphorylates p53 at serine 215 to promote liver cancer metastasis. Cancer Res 2016;76:5732-5742.
366. Ma KW, Cheung TT, Chok KS, **Ng IO**, Chan SC, Poon RT, Fan ST, Lo CM. The effect of wide resection margin in patients with intrahepatic cholangiocarcinoma - a single center experience. Medicine (Baltimore) 2016;95:e4133.
367. Ho DW, Lo RC, Chan LK, **Ng IO**. Molecular pathogenesis of hepatocellular carcinoma. Liver Cancer 2016 5:290–302 (*Editor's choice*).
368. Mao X, Wong SY, Tse EY, Ko FC, Tey SK, Yeung YS, Kwan M, Lo RC, **Ng IO**, Yam JW. Hypoxia-induced caveolin-1 upregulates S100P contributing to tumorigenesis and metastasis of hepatocellular carcinoma. Cancer Res 2016; 76:7242-7253.
369. Ho DW*, Chan LK*, Chiu EY, Xu IM, Poon RT, Cheung TT, Lo IL, Lam PW, Tang CN, Tang VW, Yau DT, Li MX, Wong CM, **Ng IO**. TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication. Gut 2017; 66:1496-1506. (*Contributed equally to the work)
370. Leong KW, Cheng CW, Wong CM, **Ng IO**, Kwong YL, Tse E. miR-874-3p is down-regulated in hepatocellular carcinoma and negatively regulates PIN1 expression. Oncotarget 2017; 8:11343-11355.

371. Ching RH, Sze KM, Lau EY, Lee JM, **Ng IO***, Lee TK*. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway. *Oncotarget* 2017; 8 :23507-23516. *Co-corresponding authors.
372. Cui CP, Wong CC, Kai AK, Ho DW, Lau EY, Tsui YM, Chan LK, Cheung TT, Chok KS, Chan AC, RC Lo, Lee JM, Lee TK, **Ng IO**. SENP1 promotes hypoxia-induced cancer stemness by HIF-1 α deSUMOylation and SENP1/HIF-1 α positive feedback loop. *Gut* 2017; 66:2149-2159.
373. Yang Y, Zhou Y, Hou J, Bai CM, Li Z, Fan J, **Ng IO**, Zhou W, Sun H, Dong Q, Lee JM, Lo CM, Man K, Yang Y, Li N, Ding G, Yu Y, Cao X. Hepatic IFIT3 predicts interferon- α therapeutic response in patients of hepatocellular carcinoma. *Hepatology* 2017; 66:152-166.
374. Lee D, Xu IM, Chiu DK, Lai RK, Tse AP, Li LL, Law CT, Tsang FH, Wei LL, Chan CY, CM Wong, **Ng IO***, Wong CC*. Methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L) of the folate cycle confers cancer cell metabolic and growth advantages. *J Clin Invest* 2017;127: 1856-1872. *Co-corresponding authors.
375. Tsui YM, Sze KM, Tung EK, Ho DW, Lee TK, **Ng IO**. Dishevelled-3 phosphorylation is governed by HIPK2/PP1C α /ITCH axis and the non-phosphorylated form promotes cancer stemness via LGR5 in hepatocellular carcinoma. *Oncotarget* 2017; Jun 13;8:39430-39442.
376. Wei LL, Law DC, Lau JC, Au SL, Lee JM, Wong CC, **Ng IO***, Wong CM*. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. *J Hepatol* 2017; 67:758-769. *Co-corresponding authors.
377. Chan KK, Leung CO, Wong CC, Ho DW, Chok KS, Lai CL, **Ng IO***, Lo RC*. Secretory Stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway. *Cancer Lett* 2017;403:330-338. *Co-corresponding authors.
378. Ma MK, Lau EY, Lo J, Ho NP, Ma S, Lin CH, Copland JA, Ding J, Lo RC, **Ng IO***, Lee TK*. Targeting liver-tumor initiating cells via hampering Stearoyl-CoA Desaturase (SCD1) mediated ER stress. *J Hepatol* 2017; 67:979-990. *Co-corresponding authors.
379. Lo RC, Chan KK, Chok KS, **Ng IO**. Liver allograft biopsies with histological cholestasis – A clinicopathologic study of 254 cases from a single center. *J Clin Path* 2018; 71:72-78.
380. Lo RC, Leung CO, Chok KS, **Ng IO**. Variation of stemness markers expression in tumor nodules from synchronous multi-focal hepatocellular carcinoma - An immunohistochemical study. *Diagn Pathol* 2017;12:56.
381. Chiu DK, Tse AP, Xu IM, Lai RK, Koh HY, Tsang FH, Wei LL, Wong CM, **Ng IO***, Wong CL*. Hypoxia inducible factor-1 (HIF-1) promotes myeloid-derived suppressor cell (MDSC) accumulation through ectonucleoside triphosphate diphosphohydrolase 2 (ENTPD2) in cancer. *Nat Commun* 2017; 8:517. *Co-corresponding authors.
382. Tey SK, Tse E, Mao X, Ko F, Wong A, Lo RC, **Ng IO**, Yam JW. Nuclear Met contributes to tumorigenesis and metastasis of hepatocellular carcinoma by activating TAK1/NF- κ B pathway. *Cancer Lett* 2017;411:150-161.
383. Tong AC, **Ng IO**, Lo MC. A case of immunoglobulin G4-related sclerosing disease involving the mandible. *HK Med J* 2017; 23:534-6.
384. Liu J, Rao Y, Cheung MP, Hui MN, Wu MH, Chan LK, **Ng IO**, Niu B, Cheah K, Sharma R, Hodgson L, Cheung M. Asymmetric localization of DLC1 defines avian trunk neural crest polarity for directional delamination and migration. *Nat Commun* 2017; 8:1185.
385. Chen M, Wei L, Law DC, Tsang FH, Shen J, Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, Wong CC, **Ng IO***, Wong CM*. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. *Hepatology* 2018; 67:2254-2270. *Co-corresponding authors.
386. Liu XB, Lo CM, Cheng Q, Ng KT, Shao Y, Li CX, Chung SK, **Ng IO**, Yu J, Man K. Oval Cells Contribute to Fibrogenesis of Marginal Liver Grafts under Stepwise Regulation of Aldose Reductase and Notch Signaling. *Theranostics* 2017;7:4879-4893.
387. Wong CM, Tsang FH, **Ng IO**. Regulatory RNAs in hepatocellular carcinoma: molecular

- functions and pathological implications. Nat Rev Gastroenterol Hepatol 2018; 15:137-151. (IF = 23.57 in 2018; ranked 1st in the category of Gastroenterology & Hepatology)
388. Lo RC*, Chan KK, Leung CO, **Ng IO***. Expression of hepatic progenitor cell markers in acute cellular rejection of liver allografts - an immunohistochemical study. Clin Transplant 2018; 32:e13203. *Co-corresponding authors.
389. Burt AD, Alves V, Bedossa P, Clouston AD, Guido M, Hübscher SG, Kakar S, **Ng IO**, Park YN, Reeves HL, Wyatt J, Yeh MM, Ellis DW. Dataset for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: Recommendations from the international collaboration on cancer reporting (ICCR). Histopathology 2018; 73:369-385.
390. Cheng BY, Lau EY, Leung DH, Ho NP, Cheng LK, Ma S, Lin CH, Lo RC, **Ng IO***, Lee TK*. IRAK1 augments cancer stemness and drug resistance via the AP-1/AKR1B10 signaling cascade in hepatocellular carcinoma. Cancer Res 2018; 78:2332-2342. *Co-corresponding authors.
391. Lo RC*, Leung CO, Chan KK, Ho DW, Wong CM, Lee TK, **Ng IO***. Cripto-1 activates Wnt/ β -catenin signaling via binding with Frizzled-7 and Disheveled 3 to regulate stemness phenotypes in hepatocellular carcinoma. Cell Death Differ 2018; 25:1426-1441. *Co-corresponding authors.
392. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, Kagen A, Klimstra D, Komuta M, Kondo F, Miksad R, Nakano M, Nakanuma Y, **Ng IO**, Paradis V, Park YN, Quaglia A, Roncalli M, Roskams T, Sakamoto M, Saxena R, Sempoux C, Sirlin C, Stueck A, Thung S, Tsui WMS, Wang XW, Wee A, Yano H, Yeh M, Zen Y, Zucman-Rossi J, Theise N. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology 2018; 68:113-126.
393. Tse AP, Sze KM, Shea QT, Chiu EY, Tsang FH, Chiu DK, Zhang MS, Lee D, Xu IM, Chan CY, Koh HY, Wong CM, Zheng YP, **Ng IO**, Wong CC. Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. Oncogenesis 2018; 7(5):44.
394. Lim CY, Lee YH, Pan L, Lai LY, Chua JH, Wasser M, Lim KH, Yeong PS, Toh HC, Lee SY, Chan CY, Goh BK, Chung AY, Heikenwalder M, **Ng IO**, Chow PK, Albani S, Chew V. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut 2019; 68:916-927.
395. Law CT, Wei L, Tsang FH, Xu IM, Lai R, Ho DW, Lee JM, Wong CC, **Ng IO**, Wong CM. Chromatin remodeler HELLS is an epigenetic driver for hepatocellular carcinoma progression. Hepatology 2019; 69:2013-2030.
396. Mao X, Tey SK, Ko FC, Kwong EM, Gao Y, **Ng IO**, Cheung ST, Guan XY, Yam JW. C-terminal truncated HBx protein activates caveolin-1/LRP6/ β -catenin/FRMD5 axis in promoting hepatocarcinogenesis. Cancer Lett 2019;444: 60-69.
397. Ma W[#], Ho DW[#], Sze KM[#], Tsui YM, Chan LK, Lee JM, **Ng IO**. APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity. Mol Carcinog 2019; 58:643-653. [#]contributed equally.
398. Lee D, Xu IM, Chiu DK, Leibold J, Tse AP, Chan CY, Lai RK, Cheung TT, Chok SH, Wong CM, Lowe S, **Ng IO***, Wong CC*. Induction of oxidative stress via inhibition of thioredoxin reductase 1 is an effective therapeutic approach for hepatocellular carcinoma. Hepatology 2019; 69:1768-1786. *Co-corresponding authors.
399. Tsang FH, Law CT, Tang CT, Cheng CL, Chin DW, Tam VW, Wei L, Wong CC, **Ng IO***, Wong CM*. Aberrant super-enhancer landscape in human hepatocellular carcinoma. Hepatology 2019; 69:2502-2517. *Co-corresponding authors.
400. Tan HW, Leung CO, Chan KK, Ho DW, Leung MS, Wong CM, **Ng IO**, Lo RC. Deregulated GATA6 modulates stem cell-like properties and metabolic phenotype in hepatocellular carcinoma. Int J Cancer 2019; 145:1860-1873.
401. Ho DW*, Tsui YM*, Sze KM, Chan LK, Cheung TT, Lee E, Sham PC, Tsui SK, Lee TK, **Ng IO**. Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and

- stemness-related subpopulations in liver cancer. Cancer Lett 2019; 459:176-185. (*equal contribution)
402. Chan LK, **Ng IO**. Proteomic profiling in liver cancer: Another new page. Transl Gastroenterol Hepatol 2019; Jun 21;4:47. (Editorial commentary).
 403. Shen J, Chen M, Lee D, Law CT, Wei L, Tsang FH, Chin WC, Cheng CL, Lee JM, **Ng IO**, Wong CC, Wong CM. Histone Chaperone FACT complex mediates oxidative stress response to promote liver cancer progression. Gut 2020; 69:329-342.
 404. Wei L, Lee D, Law CT, Zhang MS, Shen J, Chin DW, Zhang A, Tsang FH, Wong CL, **Ng IO**, Wong CC, Wong CM. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat Commun 2019;10:4681.
 405. Leung Z, Ko FC, Tey SK, Kwong EM, Mao XW, Liu BM, Ma AP, Fung YM, Che CM, Wong DK, Lai CL, **Ng IO**, Yam JW. Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells. J Exp Clin Cancer Res 2019; 38:423.
 406. Leung CO*, Tong M*, Chung KP, Zhou L, Che N, Tang KH, Ding J, Lau EY, **Ng IO**, Ma S, Lee TK. Overriding adaptive resistance to sorafenib via combination therapy with SHP2 blockade in hepatocellular carcinoma. Hepatology 2019; Oct 14. (*equal contribution)
 407. Chan LK, **Ng IO**. Joining the dots for better liver cancer treatment. Nat Rev Gastroenterol Hepatol 2020; 17:74-75.
 408. Fako V, Martin SP, Pomyen Y, Budhu A, Chaisaingmongkol J, Franck S, Lee JM, **Ng IO**, Cheung TT, Wei X, Liu N, Ji J, Zhao L, Liu Z, Jia HL, Tang ZY, Qin LX, Kloeckner R, Marquardt J, Greten T, Wang XW. Gene signature predictive of hepatocellular carcinoma patient response to transcatheter arterial chemoembolization. Int J Biol Sci 2019;15:2654-2663.
 409. Leung HW*, Lau EY*, Leung CO, Lei MT, **Ng IO**, Yun YP, Cai SY, Yu HJ, Ma S, Lee TK. NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma. Cancer Lett 2020; 476:48-56. (*equal contribution)
 410. Sze KM*, Ho DW*, Chiu YT, Tsui YM, Chan LK, Lee JM, Chok KS, Chan AC, Tang CN, Tang VW, Lo IL, Yau DT, Cheung TT, **Ng IO**. Novel cis-activation harnessing host ELF4 and HBV integrated at the TERT promoter to enhance hepatocarcinogenesis. Hepatology 2020; 14 March 2020. (*equal contribution)

Manuscript in press:

2. Tsui YM*, Chan LK*, **Ng IO**. Cancer stemness in liver cancer: mechanisms and translational potential. Br J Cancer 2020; in press. (*equal contribution)
3. Yang X, Hu F, Liu JA, Yu S, Cheung MP, Liu X, **Ng IO**, Guan XY, Wong KK, Sharma R, Lung HL, Jiao Y, Lee LT, Cheung M. Nuclear DLC1 exerts oncogenic function through association with FOXK1 for synergistic activation of MMP9 expression in melanoma. Oncogene 2020; in press.

Manuscripts submitted:

1. Chen M, Shen J, Law CT, Wang G, Cheng CL, Chin DW, Sharma R, Yuen VW, Lee JM, Wong CC, **Ng IO**, Wong CM. tRNA N1-methyladenosine methyltransferase TRMT6 promotes liver cancer stemness through regulating tRNA/codon-dependent Nestin and CD44 expression. Nat Cell Biol, in revision.
2. Chan LK*, Ho DW, Kam CS, Chiu YT, Lo IL, Yau DT, Cheung E, Tang CN, Tang VW, Lee TK, Wong CC, Chok KS, Chan AC, Cheung TT, Wong CM, **Ng IO***. p90 Ribosomal S6 Kinase 2 (RPS6KA3) inactivating mutations potentiate the MAPK signaling in cancer progression and support cholesterol metabolism. J Hepatol, under review. *Co-corresponding authors.
3. Chiu DK, Tse AP, Law DC, Xu IM, Lee D, Chen M, Lai RK, Yuen VW, Ho DW, Wong CM,

- Zhang H, **Ng IO**, Wong CC. Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway. Cell Death Dis, in revision.
4. Jiang DK, Deng J, Dong C, Song C, Ma X, Xiao Q, Zhang S, Shi Z, Zhou B, Yang C, Qu X, Zhu M, Ge Z, Conran C, Zheng L, **Ng IO**, Hou J, Yu L, Xu J, Sham PC, Cao G, Hu Z, Li M. Knowledge-based genetic association study of hepatitis B virus related hepatocellular carcinoma in Chinese populations. Submitted for publication.
 5. Lee D, Zhang MS, Tsang FH, Bao MH, Xu IM, Lai RK, Chiu DK, Tse AP, Law DC, Chan CY, Yuen VW, Chui NN, **Ng IO**, Wong CM, Wong CC. Adaptive and constitutive activations of malate enzymes confer liver cancer multi-layered protection against ROS. J Hepatol, under review.
 6. Yeung MC, Cheung KP, Cheung TT, **Ng IO**, Shek WH. KRAS mutation testing on endoscopic ultrasound-guided fine-needle aspiration samples improves the diagnostic accuracy of pancreatic cancer. Submitted for publication.

2. EDITORSHIP OF SCHOLARLY JOURNALS AND BOOKS

Journal Editorial Boards

2018 - 2021	Hepatology (Associate Editor) (IF = 14.97 in 2018; ranks 5/84 in the category of Gastroenterology & Hepatology)
2019 - 2024	Journal of Hepatology (IF = 18.946 in 2018; ranks 3/84 in the category of Gastroenterology & Hepatology)
2016 - 2021	Gastroenterology (International Consultant) (IF = 19.23 in 2018; ranks 1/84 in the category of Gastroenterology and Hepatology)
2019 - Present	EBioMedicine (Advisory Board member)
2017 - 2019 & 2009 - 2011	Hepatology (IF = 14.97)
2019 - Present	Liver Cancer International
2015 - Present	Oncogenesis (Nature Partner Journal) (IF = 6.854)
2012 - Present	Liver Cancer (IF = 5.944)
2009 - Present	Genes and Cancer
2013 - 2019	Journal of Hepatocellular Carcinoma
2008 - 2011	PLoS ONE (Academic Editor)
2007 - 2012	Liver International (Associate Editor) (Official journal of International Association for the Study of the Liver)
2000 -	Journal of Gastroenterology and Hepatology
2000 - 2008	Asian Journal of Surgery
2002 - 2009	Asian Journal of Oral and Maxillofacial Surgery
1999 - 2005	Journal of Clinical Oncology (Chinese version)
2009 Dec	Proceedings of the National Academy of Science, USA - Direct Submission Editor

Ad Hoc Reviewer for International Journals (in alphabetical order)

American Journal of Transplantation, Cancer, Cancer Cell, Cell Reports, Cancer Journal, Cancer Letters, Cancer Research, Clinical Cancer Research, Differentiation, The European Journal of Cancer, Expert Reviews in Molecular Medicine, Gastroenterology, Gene, Hepatology, Histology and Histopathology, Human Pathology, International Journal of Cancer, JAMA, Journal of Biomedical Science, Journal of Cancer Research and Clinical Oncology, Journal of Cellular and Molecular Medicine, Journal of Experimental & Clinical Cancer Research, Journal of Hepatology, Lancet Oncology, Life Sciences, Liver, Nature Communications, Nature Medicine, Nature Signaling, Neoplasia, Oncogene, and World Journal of Surgery.

International Advisor to Books

General and Systematic Pathology by Underwood JCE and Cross SS, 5th edition, Elsevier 2009.

3. INVITED LECTURES AND PRESENTATION IN INTERNATIONAL/REGIONAL CONFERENCES/INSTITUTIONS
--

'Pathology of hepatocellular carcinoma', University of Calgary, Canada, 1990

'Liver tumours', Day Course on Liver Pathology, the International Academy of Pathology, 1992

'Pathobiological prognostic factors in hepatocellular carcinoma', 4th Congress of the Asia Pacific Association of Societies of Pathologists, Beijing, 1994

'Prognostic pathobiological factors in hepatocellular carcinoma', International Symposium on Hepatology, Hong Kong, 1994

'p53 gene mutation in hepatocellular carcinoma in Hong Kong', Third Joint Meeting of International Academy of Pathology Chinese Division and Chinese Society of Pathology, Beijing, China, 1994

'Pathology and pathological prognostic factors of hepatocellular carcinoma', First Hong Kong International Cancer Congress, Hong Kong, 1994

'p53 gene mutation in hepatocellular carcinoma in Hong Kong', XX International Congress of International Academy of Pathology, 1994

'Possible causes for the better survival in female patients with hepatocellular carcinoma', International Symposium of Hepatology 1995, Hong Kong, 1995

'Epidemiologic aspects in hepatocellular carcinoma', Second Hong Kong International Cancer Congress, Hong Kong, 1995

'Molecular aspects of hepatocellular carcinoma', 3rd International Conference of Gastroenterology, Hong Kong & Shanghai, November, jointly organized by Gastroenterology Societies of America, Australia, Hong Kong, Japan and China, 1995

'Role of insulin-like growth factor II in hepatocellular carcinoma', International Symposium on Hepatology, November, Hong Kong, 1996

'Contribution of a histopathology laboratory in patient care', Scientific Meeting, the Institute of Biomedical Science, Hong Kong 1996

'Expression of multidrug resistance gene in cancers - a perspective in oral and liver cancers', School of Basic Medical Sciences, Beijing Medical University, China, August 1997

'Determinants of long term survival in hepatocellular carcinoma', International Symposium in Hepatology, Beijing, China, August 1997

'Molecular and cellular pathology of hepatocellular carcinoma', Beijing Medical University, Beijing, China, August 1997

'Expression of multidrug resistance gene in oral cancers', University of California, San Francisco, U.S.A., April 1997

'Hepatocellular carcinoma - determinants of long term survival', 11th Biennial Congress, Asian Surgical Association, March, Hong Kong, 1997

'Molecular pathology of hepatocellular carcinoma', Shanghai Cancer Institute, Shanghai, China, December 1997

'Molecular and cellular pathology of hepatocellular carcinoma', Alimentary Disease Week Hong Kong (jointly organized by American Gastroenterological Association, Gastroenterological Society of Australia, Hong Kong Society of Gastroenterology, the Japanese Society of Gastroenterology, Hong Kong Association for the Study of Liver Diseases and International Conference on Ulcer Research), Hong Kong, December 1997

'Molecular events in hepatocellular carcinoma - p53 and p21', 5th Hong Kong International Cancer Congress, Hong Kong, November 1998

'Differential higher expression of VEGF-receptor Flt-1 but not VEGF is present in hepatocellular carcinoma', Plenary presentation, Annual meeting, International Association for the Study of Liver Diseases, Chicago, November 1998

'Molecular aspects of hepatocellular carcinoma', Cancer Institute, West China University of Medical Sciences, Chengdu, July 1999

'Angiogenesis and hepatocellular carcinoma', Henan Medical School, China, February 2000

'Gene transfer targeted to hepatocellular carcinoma', Henan Medical School, China, February 2000

'Microsatellite alterations and expression of cell cycle regulators in oral cancer', University of California, San Francisco, U.S.A., March 2000

'The prognostic pathobiological features and angiogenesis in hepatocellular carcinoma', Fourth Military Medical University, Xian, China, April 2000

'Targeted gene therapy and molecular aspects in hepatocellular carcinoma', Fourth Military Medical University, Xian, China, April 2000

'Molecular events in the pathogenesis of hepatocellular carcinoma', Liver Diseases in the New Millennium (Fourth Shanghai International Symposium on Liver Cancer and Hepatitis), Shanghai, China, September 2000

'Histological activity of noncancerous livers in hepatocellular carcinoma', Shanghai Second Medical University, Shanghai, China, December 2000

'High-density allelotyping of chromosome 8p in hepatocellular carcinoma', Liver Cancer Institute, Fudan University, Shanghai, China, December 2000

'Molecular pathology of hepatocellular carcinoma in Hong Kong', Molecular Genetic Basis of Cancer, Advanced Study Institute, Hong Kong, January 2001

'Molecular genetic study of hepatocellular carcinoma', 2nd Scientific Meeting, Centre for the Study of Liver Disease, HKU, Hong Kong, February 2001

'Molecular genetic studies of hepatocellular carcinoma' (*PLENARY SESSION*), Asian-Pacific Conference of Tumor Biology 2001, Beijing, China, September 2001

'Significance of histological activity in HBV-associated hepatocellular carcinoma', 3rd Scientific Meeting, HKU Centre for the Study of Liver Disease, Hong Kong, February 2002

'Cirrhosis and hepatocellular carcinoma', Shanghai International Symposium of Cirrhosis and Its Complications, Shanghai, China, March 2002

'Molecular advances in hepatocellular carcinoma', Nanjing University, Nanjing, China, October 2002

'Hepatocellular carcinoma - Molecular oncology', 9th Hong Kong International Cancer Congress and 18th World Congress of the International Society for Digestive Surgery, Hong Kong, December 2002

'Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma', 4th Scientific Meeting, HKU Centre for the Study of Liver Disease, Hong Kong, February 2003

'Genetic alterations in hepatocellular carcinoma', Institute of Liver Studies, King's College Hospital, London, U.K., March 2003

'Characterization of candidate tumour suppressor genes in hepatocellular carcinoma', Pasteur Institute, Paris, France, March 2003

'Novel tumour suppressor genes in hepatocellular carcinoma', Inserm U434, Institut de génétique moléculaire, Paris, France, March 2003

'Novel molecular approaches to diagnosis and management of liver cancer', American Society for Investigative Pathology - Experimental Biology 2003, at Workshop on 'Liver Pathobiology: Molecular and Cellular Basis of Liver Cancer', San Diego, USA, April 2003

- ‘Role of the pathologist in hepatocellular carcinoma’**, Hong Kong Surgical Forum, University of Hong Kong, Hong Kong, July 2003
- ‘Frequent chimerism in transplanted livers’**, 5th Scientific Meeting, HKU Centre for the Study of Liver Disease, Hong Kong, February 2004
- ‘Molecular studies in hepatocellular carcinoma’**, Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, USA, March 2004
- ‘Genetic instability and novel genes in hepatocellular carcinoma’**, Genomics, Proteomics and Therapeutics in Cancer Research Conference, Cancer Research Centre, Faculty of Medicine, The University of Hong Kong, October 2004
- ‘RNA interference’**, Hong Kong International Cancer Congress, Hong Kong, November 2004
- ‘Molecular and genetic studies of hepatocellular carcinoma’**, Frontiers in Biomedical Research, Faculty of Medicine, The University of Hong Kong, December 2004
- ‘Chimerism in transplanted livers’**, Asian Pacific Association for the Study of Liver Disease, New Delhi, India, December 2004
- ‘Pathology of hepatocellular carcinoma’**, Surgical Workshop in HCC, 4th International Meeting of Hepatocellular Carcinoma: Eastern and Western Experiences, Hong Kong, December 2004
- ‘Molecular studies of HCC’**, 4th International Meeting of Hepatocellular Carcinoma: Eastern and Western Experiences, Hong Kong, December 2004
- ‘Chromosomal instability and novel genes in HCC’ (*State-of-the-Art Lecture*)**, 5th Scientific Meeting, HKU Centre for the Study of Liver Disease, Hong Kong, January 2005
- ‘RNA interference in hepatocellular carcinoma’**, Fourth Asia-Pacific International Academy of Pathology Congress (IAP2005), Beijing, August 2005
- ‘Pathology and molecular genetics of liver cancer’**, Symposium on liver cancer: Hope for our future generations, The Hong Kong Anti-Cancer Society, Hong Kong, August 2005
- ‘Virus to cancer - how?’**, World Congress of Gastroenterology 2005 Meeting ‘Global Goals in Gastroenterology: Expanding Horizons for the 21st Century’, Montréal, Canada, September 2005
- ‘Molecular and genetic alterations in hepatocellular carcinoma’**, Symposium on Advances in Cancer Biology, 18th Asia Pacific Cancer Conference, Seoul, Sept 2005
- ‘Multistep process of hepatocarcinogenesis’**, Frontiers in Biomedical Research, Faculty of Medicine, The University of Hong Kong, December 2005
- ‘Pathological diagnosis of HCC and beyond’**, Shanghai - Hong Kong International Liver Congress 2006, Shanghai, March 2006
- ‘HBV and genetic alterations in hepatocellular carcinoma’**, Princess Margaret Hospital, University of Toronto, March 2006
- ‘Molecular pathology and genetic alterations in hepatocellular carcinoma’**, Laboratory of Experimental Carcinogenesis, National Institute of Health, Bethesda, USA, April 2007
- ‘Epigenetic gene expression profiling to identify frequently silenced candidate tumor suppressor genes in cancers’**, 5th Asia Pacific International Academy of Pathology Congress, Singapore, May 2007
- ‘Molecular characterization of human hepatocellular carcinoma – Tumor suppressor genes’**, American Association for Cancer Research 2008 Annual Meeting, San Diego, USA, April, 2008
- ‘Molecular pathology and genetic alterations of liver cancer’**, International Liver Congress 2008, Hong Kong, June 2008
- ‘HBV-associated hepatocarcinogenesis and ROCK2 in HCC’**, Laennec Society meeting 2008, Padua, Italy, July 2008

- ‘Carcinogenesis of hepatocellular carcinoma’**, 2008 International Liver Cancer Symposium, Seoul, Korea, September 2008
- ‘Molecular basis of cancer – tumor suppressor genes’**, Yongsei University, Seoul, Korea, September 2008
- ‘Liver cancer as a curable/deadly disease from the perspective of histopathology and research in tumour characteristics’**, Consultants’ Meeting on development of guidelines for the palliative management of common cancers using radiotherapy in limited resource settings: liver cancer, IAEA Headquarters, The United Nations, Vienna, Austria, October 2008
- ‘Molecular pathology and genetic alterations in liver cancer’**, Singapore Cancer Symposium, Institute of Molecular and Cell Biology, Singapore, October 2008
- ‘Molecular pathology and genetic alterations in liver cancer’**, Mini-symposium, Institute of Biochemistry and Cell Biology, SIBS, Shanghai, October 2008
- ‘HBx and HCC’**, 19th Conference, Asian Pacific Association for the Study of Liver, Hong Kong, February 2009
- ‘Molecular pathogenesis of hepatocellular carcinoma’**, Frontier in Medical Sciences 2009 – Symposium on New Concepts and Approaches in Primary Liver Cancer Research, Shanghai, October 2009
- ‘Molecular pathology of liver cancer’**, Department of Oncology, Hammersmith Hospital, Imperial College, London, UK, November 2009
- ‘Cancer stem cell and carcinogenesis’**, Avison Biomedical Symposium 2010, Yonsei University College of Medicine, Seoul, February 2010
- ‘Molecular pathogenesis of hepatocellular carcinoma’**, 20th Conference, Asian Pacific Association of the Study of the Liver, Beijing, March 2010
- ‘MicroRNA in liver cancer’**, Laennec Liver Pathology Society Meeting, Seoul, Korea, May 2010
- ‘Wnt/ β -catenin cell signaling in HCC’**, Laennec Liver Pathology Society Meeting, Seoul, Korea, May 2010
- ‘MicroRNA in liver cancer’**, Shangdong University, September 2010
- ‘Liver nodules – a diagnostic approach’**, Shangdong University, September 2010
- ‘Molecular & genetic advances in hepatocellular carcinoma - Molecular and genetic diagnostic and prognostic markers in HCC’**, International Liver Symposium 2011, Gurgaon, India, August 2011.
- ‘HCC: Biomarkers & Stratification’**, Fifth Annual Conference, International Liver Cancer Association, Hong Kong, September 2011
- ‘Molecular genetic study in HCC: MicroRNA deregulation in multistep hepatocarcinogenesis’** Eastern Hepatobiliary Surgery Hospital, Shanghai, October, 2011
- ‘Do primary HCCs already harbor specific genetic alterations that confer a metastatic capacity to the tumors?’** Laennec Liver Pathology Society Meeting, Heidelberg, Germany, May 2012
- ‘Liver cancer stem cells in hepatocellular carcinoma’**, 2012 Cold Spring Harbor Asia Conference on Liver Metabolism, Disorders and Cancer, Suzhou, China, May 2012
- ‘MicroRNA deregulation in multistep hepatocarcinogenesis’**, Symposium on Translational Medicine for Cancer of Digestive Systems, 2012 Forum of Sino-American Translational Medicine, Shanghai, June 2012
- ‘Pathology and pathogenesis of HCC’**, The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting - A Bridge to a Consensus on HCC Management, Shanghai, China, July 2012
- ‘Liver cancer stem cells in hepatocellular carcinoma’**, The 7th Princess Chulabhorn International Science Congress -Cancer: from Basic Research to Cure, Bangkok, Thailand, November 2012
- ‘C-terminal truncated HBx is associated with cell invasiveness via c-Jun/MMP10 activation in HCC’**, Annual Meeting, the Laennec Liver Pathology Society Annual Meeting, Singapore, May 14-17, 2013.

‘HCC research: Molecular drivers and signalling pathway’, 23rd Conference of the Asian Pacific Association for the Study of the Liver (APASL), Singapore, June 6-10, 2013

‘Molecular pathogenesis of hepatocellular carcinoma’, 19th Annual Meeting, Korean Association for the Study of the Liver, Seoul, Korea, June 13-15, 2013

‘Recent updates in liver cancer stem cells’, the 8th IAP Asia Pacific Congress, Busan, South Korea, September 6, 2013

‘HCC classification based on pathological markers’, International Liver Cancer Association 7th Annual Conference - ILCA-EASL-NCI-AASLD Workshop on Molecular Classification and Biomarkers in HCC, Washington, DC, USA, September 12, 2013

‘Liver cancer stem cells’, 2013 Shanghai International Symposium on Cancer Stem Cells, Shanghai, China, October 17-19, 2013.

‘Liver cancer stem cells’, Asian Pacific Association for the Study of Liver Annual Meeting 2014, Brisbane, Australia, March 12-15, 2014.

‘Molecular pathogenesis of hepatocellular carcinoma’, Asian Oncology Summit 2014, organized by Elsevier, Organization for Oncology and Translational Research, and The Lancet Oncology, Kuala Lumpur, April 11-13, 2014.

‘Hepatocellular carcinoma: molecular pathogenesis and liver cancer stem cells’, Cold Spring Harbor Asia meeting on Liver Metabolism, Diseases and Cancer, in Suzhou, China, May 19-23, 2014.

‘Dishevelled 3 (Dvl3) is overexpressed in hepatocellular carcinoma and promotes cancer stemness’, International Liver Cancer Association Annual meeting, Kyoto, September 2014.

‘Pre-clinical drug testing platform in HCC - A step closer to personalized cancer therapy’, Laennec Society Meeting, Paris, June 24-27, 2015.

‘Hepatocellular carcinoma - molecular pathogenesis, cell signaling, and cancer stem cells’, Asian Pacific Primary Liver Cancer Expert (APPLE) Meeting, Osaka, July 3-5, 2015.

‘Hepatocellular carcinoma – molecular pathogenesis, cell signaling and cancer stem cells’, at State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, October 2015.

‘Hepatocellular carcinoma - molecular pathogenesis, cell signaling, and cancer stem cells’, The World Academy of Science Annual Meeting, Vienna, November 2015.

State-of-the-art lecture: ‘Fibrosis-dependent mechanism of hepatocarcinogenesis’, Asian Pacific Association for the Study of Liver Single Topic Conference 2016, Busan, Korea, April 8-10, 2016.

‘New targets in hepatocellular carcinoma – Liver cancer stem cells’, International Liver Cancer Association 10th Annual Meeting, Vancouver, Canada, September 8-11, 2016.

‘Fibrosis-dependent mechanism of hepatocarcinogenesis’, Annual symposium, State Key Lab for Liver Research, Hong Kong, October 2016.

‘Liver cancer - beyond histopathology....’, Hong Kong Pathology Forum, Hong Kong, February 10-11, 2017.

‘Implications of liver cancer stem cells for a new therapeutic target’, Asian Pacific Association for the Study of Liver meeting, Shanghai, February 16-19, 2017.

‘TSC 1 and 2 mutations for molecular stratification of HCC - a step closer to precision medicine’, Annual Meeting, Laennec Society of Liver Pathology, Bali, June 21-24, 2017.

‘Cancer stem cells – identification and implications as new therapeutic target’, (Sole *Keynote lecture*), CYTO Asia 2017, Singapore, October 25-27, 2017

‘Liver cancer - genetics, cell signalling, and cancer stemness and their translational implications’, Duke-NUS Medical School, Singapore, October 26, 2017

‘Molecular stratification of HCC - a step closer to precision medicine’, Asian Pacific Association for the Study of Liver meeting, New Delhi, India, March 15-18, 2018.

‘Liver cancer stem cells - Characterization and a target for prevention and treatment of HCC’, Asian Pacific Association for the Study of Liver meeting, New Delhi, India, March 15-18, 2018.

‘Molecular pathogenesis of hepatocellular carcinoma – Update on the odyssey’, Laennec Liver Pathology Society Meeting, Halifax, Canada, June 6-9, 2018.

State-of-the-Art Lecture **‘Molecular pathogenesis of hepatocellular carcinoma’**, 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2018), Seoul, Korea, July 6-8, 2018.

‘Clinical implication of molecular classifications in HCC’, 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2018), Seoul, Korea, July 6-8, 2018.

‘Targeting cancer stem cells in HCC’, 9th Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting 2018, Seoul, Korea, July 6-8, 2018.

‘Liver cancer: Updates in cell signaling and applications in personalized medicine’, Gordon Research Conference (Personalized Medicine) 2018, Hong Kong, July 29 - August 3, 2018.

Dr V. Ramalingaswami Oration **‘Molecular pathogenesis of hepatocellular carcinoma’**, Dr V. Ramalingaswami Oration, and Hepatopathology Meeting 2018, New Delhi, India, August 8, 2018.

Co-Chairperson and Speaker, **‘Molecular Diversity in HCC - Liquid Biopsy in HCC: Strengths and Limitations’**, Single Topic Workshops, International Liver Cancer Association, London September 14-16, 2018.

‘Mechanisms, Cell signaling, and Translational Applications in Liver Cancer’ Frontiers in Stem Cell and Cancer Research, Shanghai, April 9-10, 2019.

‘From Pathology to Genetics & Genomics in Liver Cancer’, the 8th International Oda Memorial Symposium, Tokyo, August 28, 2019.

‘Understanding the complexity and heterogeneity of HCC’, Asia-Pacific Primary Liver Cancer Expert Association (APPLE) meeting 2019, Sapporo, Hokkaido, August 29-31, 2019.

‘Latest updates on the pathological diagnosis of primary liver cancer’, Morning workshop, Asia-Pacific Primary Liver Cancer Expert Association (APPLE) meeting 2019, Sapporo, Hokkaido, August 29-31, 2019.

‘Understanding the complexity and heterogeneity of HCC (morphology, molecular and genomic) and its challenges’, Hong Kong Pathology Forum, Hong Kong, Feb 8, 2020.

‘Understanding the complexity and heterogeneity of HCC (morphology, molecular and genomic) and its challenges’, Symposium 2019/20 for the State Key Laboratory of Liver Research and Theme-based Research Scheme Project on Liver Cancer Stemness, Feb 29, 2020.

‘Liver cancer stemness and heterogeneity - molecular and pathological implications’, International Symposium on Viral Hepatitis and Liver Disease: Global Hepatitis Summit 2020, Taipei, Taiwan, Jun 18-21, 2020.

‘Liver Cancer Stem Cells and Stemness’, Keystone Symposia on Molecular and Cellular Biology: Cancer Stem Cells: Advances in Biology and Clinical Translation (postponed to 2021 May and in Hannover, Germany) (as the Scientific Organizer).

4. INTERNATIONAL STANDING & CONTRIBUTIONS TO KNOWLEDGE IN THE FIELD

A. International Association Committees

- 2013 - Present Member, International Liver Cancer Association (ILCA) Abstract Review Committee
- 2015 - 2017 AACR-Bayer HealthCare Hepatocellular Carcinoma Research Fellowship Scientific Review Committee
- 2015 Committee Member, Consensus Workshop (Diagnosis and treatment of pathological early HCC), Asia-Pacific Primary Liver Cancer Expert Meeting, 2015 July
- 2016 - Present Member, the ILCA Website Committee, International Liver Cancer Association (ILCA)
- 2017 - 2018 Chair, Special Interest Group “Molecular classification and signalling pathways”, ILCA
- 2017 - 2018 Member, Regional Advisory Committee on China, American Association for Cancer Research (AACR)
- 2017 - 2021 Governing Board and Executive Committee member (from 2019) and Council member (from 2017), Asia-Pacific Primary Liver Cancer Expert (APPLE) Association
- 2019 - 2021 Education Committee Chair, Asia-Pacific Primary Liver Cancer Expert (APPLE) Association

B. Visiting/Honorary Professorship

- 1997 - 1998 Visiting Professor, Shanghai Cancer Institute, Shanghai
- 1998 - 1999 Mrs. Gordon Wu Exchange Professorship, University of Hong Kong
- & 2008 - 2009

CB. International Study Group

- 2000 - International Liver Cancer Study Group with researchers from France, Germany, Italy, UK, USA, Japan, Taiwan, Hong Kong and South Africa.
(On classification of hepatocellular carcinoma)
- 2002 - International Cooperative Study Group on Hepatocellular Carcinoma (The University of Texas M.D. Anderson Medical Center, Mayo Clinic, Hôpital Beaujon, Paris, and University of Hong Kong Medical Center)
- 2007 - Laennec Society on Liver Pathology (an International liver pathology group with members from >10 countries)
- 2014 - 2020 International Collaboration on Cancer Reporting (ICCR) for the reporting of intrahepatic, and perihilar cholangiocarcinoma and hepatocellular carcinoma

D. Grant review

- 2002 Grant reviewer, the Italian Association for Cancer Research
- 2004 - 2012 Grant reviewer, Hong Kong Research Grants Council (HKRGC)
- 2004 Grant reviewer, Hong Kong Baptist University
- 2005 Grant reviewer, Biomedical Research Council (BMRC), A*STAR, the Agency for Science, Technology and Research, Singapore
- 2006 - 2012 Member, Hong Kong Research Grants Council (Biology and Medicine Panel)
- 2007 - 2009 Member, Research Grants Council Selection Committee (National Natural Science Foundation of China NSFC/RGC Joint Research Scheme)
- 2007 - Present Member, Grant Review Board, Research Office, Food and Health Bureau, The Government of Hong Kong SAR
- 2008 Grant reviewer, Association for International Cancer Research, UK
- 2019 Grant reviewer, Swiss National Science Foundation
- 2019 Grant reviewer, Whitepaper under NRF Competitive Research Programme (CRP), National Research Foundation, Singapore
- 2019 Grant reviewer, Poland National Science Center
- 2020 Grant reviewer, AIRC Foundation for Cancer Research, Italy

E. Organizing Committees of Scientific Meetings

- 1996 - 1997 Member, Organizing Committee, 110th Anniversary Scientific Congress, University of Hong Kong, October, Hong Kong
- 1997 Convener, Cancer Symposia, 110th Anniversary Scientific Congress, University of Hong Kong, October, Hong Kong
- 1999 - 2000 Member, Scientific Committee, Hong Kong International Cancer Congress, Hong Kong, December 2000
- 2000 Organizing member, Delegate of Center for the Study of Liver Disease of HKU to Beijing and Shanghai Universities and Institutes with 5 symposia held.
- 2000 Member, Organizing Committee, Liver Diseases in the New Millennium (Fourth Shanghai International Symposium on Liver Cancer and Hepatitis), September, Shanghai
- 2000 - 2002 Member, Organizing Committee, Scientific Meeting, Centre for the Study of Liver Disease, HKU, February 2001 and 2002
- 2002 -
2000 - 2002 Core member, Scientific Committee, Hong Kong International Cancer Congress
Organizer, Croucher Advanced Study Institute on 'Molecular Genetics in Cancer Research', January 2001 and January 2002
- 2002 - 2003 Co-Director, Croucher Advanced Study Institute on 'Molecular science of liver diseases: Linking basic science to clinical application', January 2003
- 2003 - 2004 Member, Organizing Committee, 4th International Meeting of Hepatocellular Carcinoma: Eastern and Western experiences (The 3rd meeting was held in Italy)
- 2003 - 2004 Director, Scientific Committee, Hong Kong International Cancer Congress 2004
- 2003 - 2006 Member, Core Scientific Committee, Hong Kong International Cancer Congress
- 2004 - 2005 Director, Croucher Advanced Study Institute on 'Molecular genetics and cell signaling in cancers', January 2005 and April 2006
- 2006 – 2008 Director, Croucher Advanced Study Institute on 'Molecular genetics and cell signaling in cancer and cancer metastasis', January 2007 and November 2008
- 2013 – 2017 Director, Croucher Summer Course in Cancer Biology in 2013, 2015 and 2017
- 2019 Scientific Organizer, Keystone Symposium on Molecular and Cellular Biology - "Cancer Stem Cells: Advances in Biology and Clinical Translation", October 2019, Hong Kong (3rd of a series of 3 Keystone Symposium ever held in Hong Kong) (postponed to 2021 May and to be held in Hannover, Germany)

5. RESEARCH GRANTS, R&D COLLABORATIONS, AND PATENTS
--

(A) Competitive Research Grants**Grant from Innovation and Technology Commission (Hong Kong SAR Government) for State Key Laboratory of Liver Research**

2010 Director, HK\$2 million per year (2010-2013); HK\$5 million per year (2013-2019); HK\$10 million per year (2019- present)

Research Grants Council (RGC)**Theme-based Research Scheme**

2016 Understanding cancer stemness in liver cancer – From regulation to translational applications (2017-2021) (T12-704/16-R) (Principal Coordinator) HK\$38 million (\$42.222 million including 10% matching from Universities)

RGC – Collaborative Research Fund

- 2007 ‘Molecular pathology of liver cancer – a multidisciplinary study’ (2007-2010) (HKU 1/06C) (PI) HK\$ 6,400,000
- 2010 ‘Molecular pathology of liver cancer – a multidisciplinary study’ (2010-2103) (PI) HK\$ 8,100,000 excluding on-cost (HK\$9,320,000 including 15% overhead to HKU)
- 2015 ‘Micro-PET for pre-clinical molecular imaging research in Hong Kong’ (Co-I) HK\$4,000,000 (excluding on-costs).

RGC – General Research Fund

- 2000 ‘Detection of genetic alterations on chromosome 8 in liver cancer by high-throughput fluorescent in-situ hybridization on tissue microarrays and by deletion mapping’ (2000-2002) (PI) HK\$ 763,200
- 2001 ‘Identification and characterization of DLC-2, a candidate tumour suppressor gene on 13q frequently deleted in liver cancer’ (2001-2004) (PI) HK\$ 954,000
- 2002 ‘Dysregulation of NF-κB signaling in liver cancer’ (2002-2005) (PI) HK\$ 1,440,000
- 2002 ‘Functional characterization of a novel liver-enriched transcription factor of the bZIP family’ (2002-2005) (Co-I) HK\$ 1,786,000
- 2002 ‘Functional conditioning of dendritic cells for DC-based tumor vaccine’ (2002-2005) (Co-I) HK\$ 876,000
- 2003 ‘Deciphering dysregulation of mitotic checkpoint control in liver cancer’ (2003-2006) (PI) HK\$ 1,653,000
- 2003 ‘Characterization of the granulin/epithelin precursor gene in liver cancer’ (2003-2006) (Co-I) HK\$ 1,074,000
- 2004 ‘Functional characterization of DLC1 gene, a novel tumour suppressor gene frequently deleted in liver cancer’ (2004-2007) (PI) HK\$ 1,986,880
- 2004 ‘Roles and regulation of group II p21-activated protein kinases - implications in cancer metastasis’ (2004-2006) (Co-I) HK\$ 939,968
- 2005 ‘Roles of p21-activated protein kinase (Pak) 1 in the pathogenesis of liver cancer’ (2005-2008) (Co-I) HK\$ 1,271,914
- 2006 ‘Significance of LRP6 coreceptor upregulation in the aberrant activation of Wnt signaling in liver cancer’ (2007-2009) (HKU 7615/06M) (PI) HK\$ 1,830,500
- 2006 ‘Characterization of tensin2, the binding partner of DLC1 tumor suppressor in liver cancer’ (2007-2009) (Co-I) HK\$ 932,500
- 2006 ‘GEP as a novel molecular target for liver cancer therapy’ (2007-2008) (Co-I) HK\$ 654,500
- 2007 ‘Nucleocytoplasmic shuttling mechanism of DLC1 tumor suppressor in liver cancer (2008-2010) (Co-I) HK\$ 1,388,110
- 2007 ‘Functional characterization of a putative tumor suppressor, AMP-activated protein kinase, in liver cancer’ (2008-2010) (Co-I) HK\$ 1,085,729

- 2008 'Role of mitotic checkpoint gene MAD1 (mitotic arrest deficient 1) in liver cancer' (2009-2011) (HKU 772608M) (PI) HK\$ 1,020,047
- 2008 'Roles of histone methyltransferases SUV39H1 and SUV39H2 in liver cancer' (2009-2011) (Co-I) HK\$ 897,578
- 2010 'Significance of cten dysregulation in hepatocarcinogenesis and cancer metastasis' (2011-2013) (HKU 775110M) (PI) HK\$ 1,032,000
- 2011 'Significance of RhoE dysregulation in liver cancer and metastasis' (2012-2014) (HKU 775811M) (PI) HK\$ 1,605,995
- 2013 'The role of lgr5 in liver cancer' (2013-2016) (HKU 775513M) (PI) HK\$ 952,636
- 2013 'Role of lysyl oxidase-like 2 (LOXL2) in the progression and metastasis of liver cancer' (2013-2015) (Co-I) HK\$779,429
- 2014 'Delineation of the role of RPS6KA3, which encodes p90 ribosomal S6 kinase 2 (RPS6KA3), and their natural mutants in liver cancer' (2014-2017) (17116414) (PI) HK\$618,408
- 2014 'Clinical relevance and roles of hypoxia-induced NDUFA4L2 in HCC progression' (2014-2016) (Co-I) HK\$701,470
- 2015 'The role of SUMO-specific protease SENP1 in liver cancer' (2015-2018) (17111315) (PI) HK\$1,198,878
- 2015 'The molecular mechanisms of hypoxia-induced myeloid-derived suppressor cell (MDSC) recruitment in liver cancer' (2015-2018) (Co-I) HK\$1,168,331
- 2016 'The role of RalA GTPase and its regulator RalGAP in liver cancer' (2016-2017) (17141416) (PI) HK\$886,420
- 2017 'The molecular regulations, roles, and clinical implications of hypoxia-induced porcupine in hepatocellular carcinoma' (2017-2020) (Co-I) HK\$ 1,014,736

RGC - National Natural Science Foundation of China (NSFC) Joint Research Grant

- 2002 'Characterization of novel genes in liver cancer' (2003-2005) (PI) HK\$ 799,126
- 2006 'Characterization of regulatory molecules of Wnt/ β -catenin signaling in liver cancer' (2007-2009) (PI) HK\$ 730,700

Health and Medical Research Fund, The Hong Kong SAR Government

- 2006 'Characterization of the roles of hepatitis B virus X protein in liver cancer' (2006-2008) (PI) HK\$ 800,000
- 2012 'Dissecting the gender disparity of hepatocellular carcinoma: Roles of HBV X protein and androgen receptor' (2013-2014) (12111092) (PI) HK\$ 604,000
- 2013 'Analysis of hepatitis B virus genomic integration and characterization of its role in hepatocarcinogenesis' (2013-2014) (Co-I) HK\$1,000,000
- 2013 'Statistical method to identify risk genes of complex diseases based on functional gene sets and networks, with a genetic data mining application to hepatocellular carcinoma' (2013-2015) (Co-I) HK\$ 999,990
- 2013 'Hepatitis B virus infection promotes hepatocellular carcinoma through HIF-1 α /LOXL2 pathway' (2013-2015) (Co-I) HK\$ 900,000
- 2013 'Analysis of hepatitis B virus genomic integration and characterization of its role in hepatocarcinogenesis' (2014-2015) (Co-I) HK\$1,000,000
- 2015 'Characterization of the roles of RhoE/ROCK pathway in regulating chemoresistance of liver cancer' (2015-2017) (12133191) (PI) HK\$ 609,000
- 2016 'Characterization of anti-CCL28 as a novel therapy to overcome sorafenib resistance in HCC' (03142966) (PI) HK\$ 1,173,296
- 2016 'Investigation of functional synergism of CENPF and FOXM1 in hepatocellular carcinoma' (Co-I) HK\$ 1,198,376
- 2016 'Targeting hypoxia-induced ectonucleoside triphosphate diphosphohydrolase 2 (ENTPD2) in hepatocellular carcinoma (HCC) development' (Co-I) HK\$1,199,952
- 2016 'The molecular mechanisms elicited by Sorafenib withdrawal in hepatocellular carcinoma treatment' (Co-I) HK\$ 1,199,952
- 2016 'Deregulation and somatic mutations of histone methyltransferase ASH1L in liver cancer' (Co-I) HK\$ 1,169,608
- 2016 'Pathological implications and functional characterizations of novel long non-coding RNA linc-CHD1L-1 in hepatocellular carcinoma' (Co-I) HK\$1,117,608

- 2017 'A comprehensive study on the effects of antioxidant supplements in liver cancer development and treatment' (04152336) (PI) HK\$1,199,900
- 2020 'Targeting the glycolytic enzyme PFKFB4 in liver cancer underlying p53 mutation: mechanistic insight and therapeutic implication' (07182546) (Co-I) HK\$1,497,150

SK Yee Medical Research Fund

- 2012 'Medical research on liver diseases for patients' betterment - A proposal from the State Key Laboratory for Liver Research' (2012-2016) (PI)
HK\$ 5,000,000-

HKU University Development Fund to State Key Laboratory of Liver Research

- 2011 HK\$ 5,000,000- over 3 years (2011-2014) (PI)
- 2015 HK\$ 2,000,000 (PI)
- 2017 HK\$ 2,000,000 (PI)
- 2018 HK\$ 2,000,000 (PI)
- 2019 HK\$ 2,000,000 (PI)
- 2020 HK\$ 2,000,000 (PI)

External grant from United Kingdom - Association for International Cancer Research (AICR)

- 2003 'Characterization of novel tumour suppressor genes, DLC1 and DLC2 genes, in liver cancer' (2003 - 2006) (Principal investigator) £112,500 (~HK\$ 1,693,000)

Innovation and Technology Fund, The Government of Hong Kong

- 2003 Innovation and Technology Support Program
'Development of novel nucleic acid therapeutics for viral infection and cancer' (2003-2005)
(Deputy Project Coordinator) HK\$ 2,313,472-
- 2011 Innovation and Technology Support Program
'The use of anti-DKK1 (anti-Dickkopf-1) monoclonal antibody for treatment of liver cancer' (2011-2012) (Project Coordinator) HK\$ 999,948-
- 2012 Innovation and Technology Support Program
'Therapeutic monoclonal antibody targeting of CD47 in liver cancer' (2012-2013) (Co-I)
HK\$1,000,000-

The Ministry of Science and Technology: China Science and Technology Exchange Center

- 2017 Innovative Study of hepatocarcinogenesis (PI) HK\$ 1,167,145-

Michael Kadoorie Funded Research in Cancer Genetics (on competitive basis)

- 2004 'Genome-wide methylation screening in search for novel tumour suppressor genes in liver cancer' (2004-2007) (PI) HK\$ 1,515,371-
- 2004 'Characterization of DLC1 gene, a novel tumour suppressor gene frequently deleted in liver cancer' (2004-2007) (PI) HK\$ 1,510,371-

Croucher Foundation Research Grant

- 1991 Study of DNA ploidy and tumour suppressor genes and their significance in relation to prognosis and causation of hepatocellular carcinoma (1991) (PI) HK\$ 493,000-

The University of Hong Kong

University Research Committee (HKU)

- 2003 A postdoctoral fellow for the research area on 'RNA interference in cancers'
~HK\$ 600,000 over 3 years
- 2004 Research Assistant Professor for the research area on 'Functional characterization of novel genes in liver cancer' ~HK\$ 900,000 over 2 years
- 2004 A postdoctoral fellow for the research area on 'Strategic identification and characterization of novel genes in liver cancer' ~HK\$ 700,000 over 3 years
- 2005 A postdoctoral fellow for the research area on 'Functional genomics of novel and important genes in liver cancer using mouse models' ~HK\$ 700,000 over 3 years

- 2007 A postdoctoral fellow for the research area on ‘Molecular pathology of liver cancer – a multidisciplinary study’ ~HK\$ 700,000 over 3 years
- 2007 Research Assistant Professor for the research area on ‘Hepatocellular carcinoma’ ~HK\$ 3.48 million over 6 years
- 2008 A postdoctoral fellow for the research area on ‘Identification of specific cancer stem cells for liver cancer therapy’ ~HK\$ 700,000 over 3 years
- 2009 A postdoctoral fellow for the research area on ‘Study of important cell signaling pathway in liver cancer for Identification of potential biomarkers’ ~HK\$ 700,000 over 3 years
- 2013 A postdoctoral fellow for the research area on ‘Strategic patient cancer-derived platform to enhance personalized medicine in liver cancer’ ~HK\$ 900,000 over 3 years
- 2014 A postdoctoral fellow for the research area on ‘Targeting cancer metabolism for novel treatments in liver cancer’ ~HK\$ 1 million over 3 years
- 2015 A postdoctoral fellow for research area on ‘Translational genetic applications towards a new algorithm targeting specific cellular pathways for liver cancer’ ~HK\$ 1 million over 3 years
- 2016 A postdoctoral fellow for research area on ‘Exploiting the vulnerabilities of liver cancer stem cells for potential efficacious treatment’ ~HK\$ 1 million over 3 years

(B) R&D collaboration with biopharmaceutical companies

Research Collaborative Fund from Pfizer Inc.

- 2010 Liver cancer research (2010 Jan - 2012 Dec) (PI) HK\$ 20,744,735-
- 2011 Characterization of DKK1 as a potential antibody target for HCC (2011-2013) (PI) HK\$ 156,000-
- 2013 New target identification or validation and precision medicine patient stratification in HCC (Aug 2013 - Aug 2015) (PI) HK\$1,317,647-

Research Collaboration with Janssen Pharmaceutica

- 2015 Target identification and validation of hepatocyte host components that enhance HBx nuclear localization and HBV replication (Nov 2015 - Oct 2016) (PI) HK\$ 1,600,000-

Research Collaboration with China Novartis Institutes for Biomedical Research

- 2015 Identification and characterization of potential therapeutic targets in HCC (Jan 2016 – Jul 2017) (PI) HK\$ 1,200,000-

Research Collaboration with Arbele (HK) Ltd (a biotech start-up company)

- 2016 CDH17 immunochemical assay and in vivo testing of CAR-T product against CDH17 (Dec 2016 – Jun 2018) (PI) HK\$370,588-

(C) Competitive Funding from External Foundation for Holding Scientific Courses

Croucher Foundation Advanced Study Institute

- 2001 ‘Croucher Advanced Study Institute on ‘Molecular genetic basis of cancer’, held in Jan 2001; Awarded HK\$ 590,000 (Organizer)
- 2002 ‘Molecular science of liver diseases: Linking basic science to clinical application’ held in Jan 2003; Awarded HK\$ 531,000 (Co-Director)
- 2004 ‘Molecular genetics and cell signaling in cancers’ held in Jan 2005 and Apr 2006; Awarded HK\$ 600,000 (Director)
- 2006 ‘Molecular genetics and cell signaling in cancers and cancer metastasis’ held in Jan 2007; Awarded HK\$ 600,000 (Director)

Croucher Summer Course

- 2012 Croucher Summer Courses in Cancer Biology, in 2013, 2015 and 2017, from Croucher Foundation; Awarded HK\$ 1,800,000- (As Director)

(C) Patents

1. The use of anti-DKK1 monoclonal antibodies in treating liver cancer (抗DKK1单克隆抗体用于治疗肝癌的用途); patent number ZL 2012 8 00165431 (approved April 2016)

- 2 The use of anti-DKK1 monoclonal antibodies in treating liver cancer. European patent No.12741908.3 - 1403 PCT/CN2012070542
3. 'Combination use of CD47 antibodies/inhibitors with Sorafenib for treatment of liver cancer', Patent application filed to US Patent Office, Sept 2015

6. TEACHING AND EXAMINERSHIP

TEACHING

□ Postgraduate teaching and supervision

A. Graduate theses supervised (The University of Hong Kong)

Ten PhD, 9 MPhil and 2 MMedSc students (with me as Principal Supervisor) and 14 PhD and 10 MPhil students (with me as Co-Supervisor) graduated.

As Principal Supervisor:

- | | |
|-------------|---|
| 1997 - 2000 | ‘Targeted gene delivery using a receptor-mediated gene transfer system and chemosensitivity in hepatocellular carcinoma’ (MPhil), KW Lee (Now as Associate Professor at HKPolyU) |
| 1997 - 2000 | ‘Significance of cell cycle regulators in human hepatocellular carcinoma and gene expression induced by cisplatin in hepatoma cell lines’ (PhD), Dr. LF Qin, M.D. (Now a Postdoctoral Fellow at Baylor Medical College, U.S.A.) |
| 1997 - 1999 | ‘Correlation of microsatellite instability and loss of heterozygosity with prognosis in hepatocellular carcinoma’ (MMedSc.), Matthew Ho (Now a Hospital Medical Technologist) |
| 1999 - 2000 | ‘A study of mutation and expression of β -catenin in hepatocellular carcinoma’ (MMedSc.), CM Wong (Now an Associate Professor at HKU) |
| 2000 - 2002 | ‘Molecular alterations on chromosome 8 in hepatocellular carcinoma’ (MPhil), KL Chan (Now a Research Fellow (Genome Damage and Stability) at University of Sussex, UK) |
| 2001 - 2003 | ‘Dysregulation of NF- κ B signaling in hepatocellular carcinoma’ (MPhil), CF Chan (Now a bioscience firm manager in Shanghai) |
| 2001 - 2003 | ‘Novel candidate tumour suppressor genes, DLC1 and DLC2, in hepatocellular carcinoma’ (PhD), CM Wong (Now an Associate Professor at HKU) |
| 2002 - 2006 | ‘Characterization of mitotic checkpoint proteins, MAD1 and MAD2, in hepatocellular carcinoma’ (PhD), Karen MF Sze (Now an Assistant Research Officer at HKU) |
| 2003 - 2005 | ‘Identification and characterization of a novel tumor suppressor gene, Deleted in Liver Cancer 2, (DLC2)’, (PhD), Thomas HY Leung (Now a Postdoctoral Fellow at HKU) |
| 2004 - 2007 | ‘Molecular studies of hepatocellular carcinoma’ (PhD), Edmund KK Tung (Now a Scientific Officer at Queen Mary Hospital, HK) |
| 2005 - 2007 | ‘mTOR signaling in hepatocellular carcinoma’ (MPhil), ICF Hui (Now a Medical Officer of the Hospital Authority) |
| 2005 - 2008 | ‘Functional studies of DLC1 (deleted in liver cancer) gene in hepatocellular carcinoma’ (PhD), Carmen CL Wong (Now as Assistant Professor at HKU; was a Croucher Postdoctoral Fellow at Johns Hopkins University) |
| 2006 - 2008 | ‘Significance of LRP6 coreceptor upregulation in the aberrant activation of Wnt signaling in hepatocellular carcinoma’ (MPhil), Betty YC Wong |
| 2006 - 2008 | ‘Study of the role of the tumor suppressor phosphatase and tensin homolog (PTEN) in hepatocellular carcinoma’ (MPhil), Lai-Ting Wong |
| 2010 - 2013 | ‘Roles of hypoxia-inducible microRNA-210 in hepatocellular carcinoma’ (PhD), Alan Kai (Now a marketing officer at biopharmaceutical company in HKU) |
| 2009 - 2013 | ‘Study of the roles of RhoE in human hepatocellular carcinoma’ (PhD), Wei Ma (Now a Technical Officer in a Technological Company in Hong Kong Science Park) |
| 2009 - 2013 | ‘Study of the roles of Dishevelled-3 in stemness and cell migration in hepatocellular carcinoma’ (PhD), Yu-Man Tsui (Now a Postdoctoral Fellow at HKU) |
| 2014 – 2016 | ‘Targeting liver-tumor initiation cells via hampering the lipogenesis pathways through stearyl-CoA desaturase’, Kin-Fai Ma (Now an MBBS medical student at HKU) |

- 2013 – 2016 ‘Transketolase (TKT), a critical enzyme in the pentose phosphate pathway (PPP), counteracts oxidative stress to drive hepatocellular carcinoma (HCC) progression’ (PhD), Iris MJ Xu (Now a Scientific Officer in Chinese University of Hong Kong)
- 2014 – 2016 ‘Functional characterization and therapeutic role of interleukin-1 receptor-associated kinase (IRAK1) in hepatocellular carcinoma’ (MPhil), Bowie Yuk Ling Cheng

As Co-supervisor:

- 1995 - 1998 ‘Prospective evaluation of Pringle maneuver in hepatectomy for liver tumours’ (PhD), Dr. Kwan Man, MD. (Now a Professor at HKU)
- 1995 - 1998 ‘Mechanism of spontaneous rupture of hepatocellular carcinoma’ (PhD), Dr. Li-xin Zhu, MD (Co-supervisor) (Now a Professor at Zhe-Jiang University, China)
- 2003 - 2005 ‘Functional characterization of DLC2 gene’, (PhD), David C.H. Ng
- 2004 - 2008 ‘Characterization of binding partners of DLC1 tumour suppressor gene in hepatocellular carcinoma’ (PhD), LK Chan (Now an Research Assistant Professor at HKU)
- 2004 - 2006 ‘PAK in hepatocellular carcinoma’, (MPhil), Helen HT Xu
- 2004 - 2005 ‘Epigenetic regulation of gene expression of cystatin 6, CST6, in hepatocellular carcinoma’, (MMedSc), Marcella KL Ma (Now a Research Assistant in UK)
- 2005 - 2007 ‘AMPK cell signaling in hepatocellular carcinoma’, (MPhil), Michael Liu
- 2005 - 2008 ‘Molecular regulations of Deleted in Liver Cancer (DLC) protein family’, (PhD), Frankie CF Ko
- 2006 - 2010 ‘bZIP transcription factors in hepatic physiology and pathology’, (PhD), CP Chan
- 2007 - 2011 ‘Epigenetic role and functions of Enhancer of Zeste Homolog 2 in hepatocellular carcinoma’, (PhD), Sandy Leung-Kuen Au
- 2008 - 2010 ‘Identification of liver tumour-initiating cells using a chemoresistant animal model’ (MPhil), Antonia Castilho (Now a medical officer in Hospital Authority, HK)
- 2009 – 2011 ‘Identification of CD47 as a novel therapeutic target for hepatocellular carcinoma’, (MPhil), Vincent Chi-Ho Cheung (Now a medical officer in Hospital Authority, HK)
- 2009 - 2011 ‘Oncogenic role of integrin-linked kinase in hepatocellular carcinoma’, (MPhil), Jenny Chan
- 2009 - 2011 ‘Epigenetic dysregulation of microRNA-9 (miR-9) in hepatocellular carcinoma’, (MPhil) Aegean HK Tam
- 2010 – 2012 ‘Role of hypoxia-induced upregulation of caveolin-1 in hepatocellular carcinoma’, (MPhil), Sivia Yuen-Sze Wong (Now a medical officer in Hospital Authority, HK)
- 2012 – 2014 ‘Functional characterization and therapeutic implication of CD47 in sorafenib resistance in hepatocellular carcinoma’, (MPhil), Jessica Lo.
- 2010 – 2013 ‘The emerging roles of non-coding RNAs in hepatocellular carcinoma’, PhD, Felice HC Tsang (Now a postdoctoral fellow in Oxford University)
- 2012 – 2015 ‘Functional characterization of cancer-associated fibroblasts in the regulation of cancer stem cell-like properties in hepatocellular carcinoma’, PhD, Yuen-ting Lau (now a scientific officer at Queen Mary Hospital)
- 2012 – 2015 ‘Deregulation of histone methyltransferases SETDB1 and G9a and their functional roles in liver cancer’ PhD, Larry L Wei
- 2011 – 2015 ‘Next generation sequencing analysis: from monogenic to polygenic disorders’, (PhD), John KL Wong
- 2013 – 2015 ‘The clinical relevance and roles of NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4-like 2 in hepatocellular carcinoma progression’, MPhil, Kit-Ho Lai

Awards to postgraduate students (as principal supervisor if not indicated otherwise)

- 1999 **Winner of Young Investigators' Award** to Lee TWK, for the paper ‘In-vitro and in-vivo efficiency of gene delivery using a novel receptor-mediated gene transfer system in hepatocellular carcinoma’, in 6th Hong Kong International Cancer Congress, Hong Kong
- 2000 **Winner of the best paper award runners-up**, Lee TWK, for the paper ‘Gene delivery using a novel receptor-mediated gene transfer system in hepatocellular carcinoma’, in 17th Meeting of International Academy of Tumor Marker Oncology, Hong Kong
- 2000 **Winner of Young Investigators' Award and Winner of Journal of Hepatology and**

- Gastroenterology Young Investigator Award*, TWK Lee, in 11th Asian Pacific Congress of Gastroenterology and 8th Asian Pacific Congress of Digestive Endoscopy
- 2002 **Winner of the Young Investigator Award**, 9th Hong Kong International Congress of Cancer and 18th World Congress of the International Society for Digestive Surgery, 2002 to Chun-Ming Wong, PhD student
- 2003 **Croucher Scholarship** to Kok-Lung Chan, MPhil graduate
- 2003 **Sir Edward Youde Fellowship** to Anthony Chun-Fung Chan, MPhil student
- 2003 **Li Ka Shing prize for the best MPhil thesis** to Kin-Wah Lee, MPhil graduate, on the thesis entitled 'Targeted gene delivery using a receptor-mediated gene transfer system and chemosensitivity in hepatocellular carcinoma'
- 2004 **AACR-ITO EN Scholar-in-Training Award** to Leung Ho Yin, Thomas, PhD student, on presentation entitled 'Characterization of novel putative tumor suppressor gene, *DLC2* (deleted in liver cancer 2), in hepatocellular carcinoma'
- 2004 **Young Investigator Award**, 4th International Meeting of Hepatocellular Carcinoma: Eastern and Western experiences, to Leung Ho Yin, Thomas, PhD student
- 2006 **Best Presentation Award**, Departmental Postgraduate Seminar, HKU, to Carmen Wong, PhD student
- 2006 **Best Presentation Award**, Departmental Postgraduate Seminar, HKU, to Michael Liu, MPhil student (as Co-supervisor)
- 2006 **Best PhD Presentation Award in Cancer**, 11th Research Postgraduate Symposium, LKS Faculty of Medicine, HKU, December to Carmen Wong, PhD student
- 2006 **Best Poster Presentation Award**, 11th Research Postgraduate Symposium, LKS Faculty of Medicine, HKU, December to Michael Liu, MPhil student (as Co-supervisor)
- 2007 **AACR-ITO EN Scholar-in-Training Award** to Edmund KK Tung, PhD student
- 2007 **Young Investigator Award**, to Carmen CL Wong, PhD student, by the Hong Kong International Cancer Congress
- 2007 **Best PhD Presentation Award in Cancer**, 12th Research Postgraduate Symposium, LKS Faculty of Medicine, HKU, December to Lo-Kong Chan, PhD student (as Co-supervisor)
- 2008 **Young Investigator Award**, to Ms Carmen CL Wong, PhD student, in the Hong Kong-Shanghai International Liver Congress 2008
- 2008 **Mary Sun Medical Scholarship** 2007-2008 to Ms Carmen CL Wong, PhD student
- 2008 **Hong Kong International Cancer Congress 2008 Young Investigator Award** to Ms Edith Tse, PhD student (as Co-supervisor)
- 2008 **Postgraduate Research Symposium 2008** Overall best PhD paper to Carmen C.L. Wong
- 2009 **Croucher Postdoctoral Fellowship** for overseas postdoctoral fellow training to Carmen C.L. Wong, PhD student
- 2009 **Dr. KP Stephen Chang Gold Medal 2008-2009** to Carmen C.L. Wong, PhD student
- 2009 **Hong Kong Young Scientist Award (Life Science)**, Hong Kong Institution of Science to Carmen C.L. Wong, PhD student
- 2009 **Hong Kong International Cancer Congress 2009 Young Investigator Award** to Sandy LK Au, PhD student (as Co-supervisor)
- 2010 **Hong Kong International Cancer Congress 2010 Young Investigator Award** to Vincent Chi-Ho Cheung, MPhil student (as Co-supervisor)
- 2010 **Li Ka Shing Prize for the Best PhD Thesis** to Carmen C.L. Wong, PhD student
- 2010 **Best PhD Presentation Prize, Research Postgraduate Symposium**, HKU Medical Faculty to Sandy L.K. Au, PhD student
- 2011 **Outstanding Research Postgraduate Student award**, the Graduate School, HKU, to Antonia Genevieve Castilho, MPhil student
- 2011 **Best Presentation Award**, Departmental Postgraduate Seminar, HKU, to Wei Ma, PhD student
- 2011 **Best PhD poster**, Postgraduate Research Symposium 2011 to Alan Kai, PhD student
- 2012 **Best Presentation Award**, Departmental Postgraduate Seminar, HKU, to Alan Kai, PhD student
- 2012 **Outstanding Research Postgraduate Student award**, the Graduate School, HKU, to Vincent CH Cheung, MPhil student
- 2012 **Best PhD poster**, Postgraduate Research Symposium 2011 to Eunice Lau, PhD student
- 2014 **Young Investigator Award**, Hong Kong International Cancer Congress 2014 to Iris Xu, PhD student
- 2015 **Outstanding Oral Presentation Award**, Hong Kong Inter-University Postgraduate Symposium

- on Life Science to Dr. Chun-Ping Cui, Postdoctoral Fellow
- 2015 *Li Ka Shing Prize for the Best MPhil Thesis* to Jessica Lo, MPhil student (co-supervisor)
- 2015 *Second runners-up, Best Oral Presenter* at 20th HKKU Medical Faculty Research Postgraduate Symposium (20th RPS) 2015, to Ms. Iris Xu, PhD student
- 2016 *Li Ka Shing Prize for the Best MPhil Thesis* to Kit-Ho Lai, MPhil student (co-supervisor)
- 2017 *Li Ka Shing Prize for the Best MPhil Thesis* to Bowie Yuk Ling Cheng, MPhil student

B. Teaching in Postgraduate Courses (The University of Hong Kong)

- 2000 - Lectures in Faculty-based Core and Specialized Modules in PhD/MPhil/MMedSc courses
- 2004 - Coordinator, Cytogenetics and Molecular Genetics of Cancer

□ **Undergraduate teaching**

A. Undergraduate (Medical) (The University of Hong Kong)

New MBBS problem-based learning (PBL) curriculum:

- 1998 - Case coordinator and panel discussant, clinicopathological conferences, year IV & V
- 1998 - Department coordinator in System-based Module, new MBBS curriculum
- 1998 - Lecturer and tutor (problem-based learning and small group teaching) in Pathology, new MBBS curriculum
- 2001 - Member, Problem-based Learning Planning Group, Faculty of Medicine
- 2001 - PBL Education Tutor

Old MBBS curriculum:

- 1981 - 1998 Panel discussant, clinicopathological conferences, years IV & V
- 1987 - 1998 Lecturer, integrated teaching sessions, M.B.B.S. year IV
- 1981 - 1999 Lecturer and tutor in Pathology, M.B.B.S. year II and III courses

B. Undergraduate (BDS, Bachelor of Dental Science) (The University of Hong Kong)

New BDS problem-based learning curriculum:

- 1998 - Coordinator and demonstrator for Practical Sessions
- 1999 - Tutor (problem-based learning), new BDS curriculum
- 1999 - 2004 Discipline consultant, new BDS curriculum

Old BDS curriculum:

- 1982 - 1999 Lecturer and Tutor, B.D.S. year II Pathology course
- 1996 - 2000 Principal Lecturer, B.D.S. year IV Applied Histopathology Course
- 1996 - 1999 Course Director, B.D.S. year II Pathology course
- 1996 - 2000 Course Director, B.D.S. year IV Applied Histopathology Course

C. Undergraduate (Bachelor of Chinese Medicine) (The University of Hong Kong)

- 2003 - Lecturer and Practical demonstrator and Tutor

□ **Teaching Innovation and Curriculum Development**

- 1997 Visit to the School of Dentistry and Medicine, University of California, San Francisco, with special emphasis on teaching of dental pathology
- 1996 Introduced clinicopathological conference for dental undergraduates in B.D.S. year IV Applied Oral Pathology Course
- 1996 - Member, Departmental Curriculum Committee
- 1997 - 2004 Discipline Coordinator for Pathology, new problem-based learning curriculum, Faculty of Dentistry
- 2001 - Member, Problem-based Learning Planning Group, Faculty of Medicine
- 1997 - Member, System-based Blocks Planning Group, new problem-based learning MBBS Curriculum, Faculty of Medicine
- 2002 - Problem-based learning Tutor Educator, Faculty of Medicine

EXAMINERSHIP

A. International Professional Examination

1999 - 2004 Examiner, Royal Australasian College of Dental Surgeons

B. Hong Kong College of Pathologists

2008 - 2012 Chief Examiner in Anatomic Pathology, the Hong Kong College of Pathologists

C. Examiner of doctorate or postgraduate theses (>15 theses)

D. Undergraduate

New problem-based learning curriculum

1998 - Examiner, MBBS year I & II

1999 - Examiner, BDS II examination

2000 Chief Examiner, MBBS II examination

Old curriculum

1996 - 1999 Chief Examiner, B.D.S. II examination in Pathology

1996 - 2001 Examiner, B.D.S. Final Examination

7. PROFESSIONAL STANDING

Member of International Committees

- 2015 - 2020 Member, Scientific Advisory Board for Zhengzhou University Academy of Medical Sciences (Dean being Professor Nicholas Lemoine, Director of Barts Cancer Institute and Queen Mary University of London)
- 2014 - 2016 International Collaboration on Cancer Reporting (ICCR) for the reporting of intrahepatic, and perihilar cholangiocarcinoma and hepatocellular carcinoma
- 2005 - Present Laennec Society on Liver Pathology (an International liver pathology group with members from >20 countries)
- 2013 - 2016 International Liver Cancer Association (ILCA) Abstract Review Committee member
- 2016 – 2017 Member, ILCA Website Committee, International Liver Cancer Association (ILCA)
- 2015 Committee Member, Consensus Workshop (Diagnosis and treatment of pathological early HCC), Asia-Pacific Primary Liver Cancer Expert Meeting 2015
- 2017 - Present Council member of Asia-Pacific Primary Liver Cancer Expert Association
- 2019 – 2021 Education chair and member of Executive Committee, Asia-Pacific Primary Liver Cancer Expert Meeting

Organizer of International Conferences

- 2001 Liver Diseases in the New Millennium (Fourth Shanghai International Symposium on Liver Cancer and Hepatitis), September 2001, Shanghai
- 2003-2004 Hong Kong International Cancer Congress, November 2004, Hong Kong
- 2003-2004 4th International Meeting of Hepatocellular Carcinoma: Eastern and Western Experiences (The 3rd meeting held in Italy), December 2004
- 2004- Present Hong Kong International Cancer Congress, Hong Kong
- 2016 Member, Advisory Committee at the 7th Asia Pacific Primary Liver Cancer Expert Meeting (APPLE 2016)

Croucher Advanced Study Institute, Hong Kong

- 2000 - 2001 Organizer, Croucher Advanced Study Institute on ‘Molecular genetic basis of cancer’, January 2001
- 2002 - 2003 Co-Director, Croucher Advanced Study Institute on ‘Molecular science of liver diseases: Linking basic science to clinical application’, January 2003
- 2004 - 2005 Director, Croucher Advanced Study Institute on ‘Molecular genetics and cell signaling in cancers’, January 2005 and April 2006
- 2007 - 2008 Director, Croucher Advanced Study Institute on ‘Molecular genetics and cell signaling in cancers and cancer metastasis’, January 2007 and November 2008

Croucher Summer Course in Cancer Biology, Hong Kong

- 2013 - 2017 Director, Croucher Summer Course in Cancer Biology, 2013, 2015 & 2017

8. ADMINISTRATION AND SERVICES

A. Hong Kong/Mainland

2010 - Present Director, State Key Laboratory of Liver Research (HKU)

B. Hong Kong

Government of the Hong Kong SAR

2017 - 2021 Member, Committee on Innovation, Technology and Re-industrialisation

Hong Kong Research Grants Council (RGC)

2006 - 2012 Member, Panel of Biology and Medicine, RGC General Grant Fund

2007 - 2009 Member, National Natural Science Foundation of China (NSFC)/RGC Joint Selection Committee

2015 - 2020 Member, Hong Kong PhD Fellowship Scheme (HKPFS) Selection Panels, Hong Kong Research Grants Council

2017 - 2020 Council Member, RGC

Hong Kong University Grants Committee (UGC)

2013 - 2015 Member, Clinical Medicine Panel, Research Assessment Exercise 2014, UGC

Grant Review Board, Research Council, Food and Health Bureau, Government of HK SAR

2007 - Present Member, Grant Review Board, Research Council, Food and Health Bureau, Government of Hong Kong Special Administrative Region

Nursing Council of Hong Kong

2007 - 2010 Member, Nursing Council of HK (Appointed by the Government of HK SAR)

2007 - 2012 Member, Accreditation Committee (to accredit Nursing Programs in HK)

C. Hong Kong College of Pathologists

1993 - 2005 Member, Subcommittee on Quality Assurance Program in Anatomical Pathology

1994 - Present Education supervisor at Pathology, Queen Mary Hospital

1996 - 2005 Member, Subcommittee on Quality Assurance Program

1996 - 2010 Inspector, for accreditation of laboratory training in Anatomical Pathology

2005 - 2007 Chairperson, Specialty Board in Anatomical Pathology

2004 - 2008 Elected Member, College Council

2008.1 - 2012.03 Chief Examiner, Anatomic Pathology

2012 - Present Examiner, Anatomic Pathology

D. The University of Hong Kong

2004 - 2017 Ad hoc member, University Research Committee

2005 - 2011 Member, University's Committee on Research and Conference Grants

2007 - 2009 Member, Promotion and Tenure Panel, Faculty of Dentistry

2009 - 2012 Member, Promotion and Tenure Panel, Faculty of Science

2008, 2012 Ad hoc member, University Selection and Promotion Committee

2007 - 2008 Member, Task Force of RGC Visit 2008

2010 - 2016 Member, Policy Board of Postgraduate Education

2010 - Present Director, State Key Laboratory for Liver Research

2011.12 – 2019.12 Head, Department of Pathology

2014 - 2017 Member, Committee of Management of Partner State Key Laboratory of Pharmaceutical Biotechnology

2014 - 2018 Member, Advisory Group on Academic Reviews

2016 - 2017 Chairman, Academic Review Panel for Faculty of Dentistry

2017 - 2019 Member, University Selection and Promotion Committee (USPC) Life Sciences Panel

E. Faculty of Medicine, The University of Hong Kong

1992 - 2000 Member, Selection Committee, HKU Medical Faculty Student Loan Fund
 1996 - 1997 Member, Organizing Committee, 110th Anniversary Scientific Congress
 1997 Convener, Cancer Symposia, 110th Anniversary Scientific Congress
 2001 - 2012 Member, Sun Yat Sen Foundation Fund for Academic Exchanges with China
 2001 - Present Member, Problem-based Learning Planning Group, Faculty of Medicine
 2002 Member, Search Committee for Chair of Pathology
 2003 - 2006 Member, Committee on Research and Conference Grants (Research Panel for Medicine)
 2004- 2007, Member, Faculty Higher Degrees Committee
 2010 - 2016.2
 2003 - 2013 Internal reviewer for RGC CERG grant applications
 2005 - 2013 Member, Faculty Research Committee
 2007 - 2013 Assistant Dean (Research)
 2010 Chairman, Research Taskforce for a Proposal for Central Grant for research in the HKU-Shenzhen Hospital

F. Faculty of Dentistry, University of Hong Kong

1997- 2004, 2011- Member, Board of Faculty of Dentistry

G. Department of Pathology, University of Hong Kong

1992 - 1999 Coordinator, Quality Assurance Program in Surgical Pathology
 1992 - 2000 Deputy-in-charge, Surgical Pathology
 1996 - 2000 Departmental co-ordinator, interdepartmental Head and Neck Seminars
 1996 - 2011 Coordinator, interdepartmental clinicopathological conference in Oral Pathology
 1996 - 2011 Member, Curriculum Committee
 2002 - 2011 Member, Convenors' Meeting (senior management group of Department)
 2002 - 2008 Chairperson, Departmental Research Postgraduate Committee
 2011 – 2019.12 Head, Department of Pathology
 2011 - 2019.12 Chairman, Convenors' Meeting (senior management group of Department)
 2013 - 2017 Chairman, Organizing Committee, Pathology Forum (yearly conference)

CLINICAL SERVICE

A. Hospital Authority

- 1995 - 2003 Member, Laboratory Workload Statistics Subcommittee, Anatomic Pathology division
 2017 - 2019 Member, Coordinating Committee in Pathology

B. Queen Mary Hospital (Teaching Hospital of HKU Medical School)

- 1996 - Honorary Consultant, Queen Mary Hospital, Hospital Authority, Hong Kong
 1990 - Key pathologist and pathologist-in-charge, Pioneer liver transplantation team at Queen Mary Hospital
 1986 - Team Supervisor in Surgical Pathology, Autopsy, and Cytology services
 1996 - 2005 Pathologist-in-charge, Oral Pathology Clinicopathological Meeting
 1996 - Pathologist providing private, large-scale cytology screening service
 2013 - Leader, Working Group of HKU Pathology for QMH redevelopment project
 2013 - Co-Chairman, Joint HA/HKU Clinical Service Meeting (Pathology)
 2015.6 - 2016.12 Deputy Chief of Service, Department of Pathology and Clinical Biochemistry
 2015.6 - Present Chairman, Anatomic Pathology Management Committee
 2017.1 – 2019.12 Chief of Service, Department of Pathology (with 5 divisions including Anatomic Pathology, Hematology, Clinical Biochemistry, Immunology, and Transplantation and Immunogenetics)

B. Liver Transplantation

- 1991 - Pathologist-in-charge and Key Pathologist, Liver Transplantation Service (Pioneer liver transplantation in Hong Kong since 1991)
 1998 - Consultations from Universities in Mainland China for liver transplantation pathology diagnosis
 2002 Providing training in diagnostic pathology to Senior Pathology Scholar (Dr. Lihua Zhang) Nanjing, Mainland China
 2004 Providing training in diagnostic pathology to Consultant Pathologist (Prof. Nancy Khin) from Myanmar, Burma